0001938046 2026-01-01 2026-03-31 0001938046 2026-05-15 0001938046 2026-03-31 0001938046 2025-12-31 0001938046 us-gaap:NonrelatedPartyMember 2026-03-31 0001938046 us-gaap:NonrelatedPartyMember 2025-12-31 0001938046 us-gaap:RelatedPartyMember 2026-03-31 0001938046 us-gaap:RelatedPartyMember 2025-12-31 0001938046 MGRX:PatentPurchasePayableMember 2026-03-31 0001938046 MGRX:PatentPurchasePayableMember 2025-12-31 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2026-03-31 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-12-31 0001938046 MGRX:SeriesCConvertiblePreferredStockMember 2026-03-31 0001938046 MGRX:SeriesCConvertiblePreferredStockMember 2025-12-31 0001938046 2025-01-01 2025-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2024-12-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2024-12-31 0001938046 us-gaap:CommonStockMember 2024-12-31 0001938046 us-gaap:WarrantMember 2024-12-31 0001938046 MGRX:SubscriptionReceivableMember 2024-12-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001938046 us-gaap:RetainedEarningsMember 2024-12-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001938046 us-gaap:NoncontrollingInterestMember 2024-12-31 0001938046 2024-12-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2025-12-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2025-12-31 0001938046 us-gaap:CommonStockMember 2025-12-31 0001938046 us-gaap:WarrantMember 2025-12-31 0001938046 MGRX:SubscriptionReceivableMember 2025-12-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001938046 us-gaap:RetainedEarningsMember 2025-12-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001938046 us-gaap:NoncontrollingInterestMember 2025-12-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001938046 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001938046 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001938046 MGRX:SubscriptionReceivableMember 2025-01-01 2025-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001938046 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001938046 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001938046 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001938046 MGRX:SubscriptionReceivableMember 2026-01-01 2026-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001938046 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2025-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2025-03-31 0001938046 us-gaap:CommonStockMember 2025-03-31 0001938046 us-gaap:WarrantMember 2025-03-31 0001938046 MGRX:SubscriptionReceivableMember 2025-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001938046 us-gaap:RetainedEarningsMember 2025-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2025-03-31 0001938046 2025-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2026-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2026-03-31 0001938046 us-gaap:CommonStockMember 2026-03-31 0001938046 us-gaap:WarrantMember 2026-03-31 0001938046 MGRX:SubscriptionReceivableMember 2026-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001938046 us-gaap:RetainedEarningsMember 2026-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2026-03-31 0001938046 us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001938046 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001938046 us-gaap:NonrelatedPartyMember 2026-01-01 2026-03-31 0001938046 us-gaap:NonrelatedPartyMember 2025-01-01 2025-03-31 0001938046 us-gaap:IPOMember 2023-03-01 2023-03-31 0001938046 us-gaap:IPOMember 2023-03-31 0001938046 MGRX:ResaleProspectusMember 2023-03-01 2023-03-31 0001938046 MGRX:ResaleProspectusMember 2023-03-31 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-03 2025-01-03 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-03 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-06 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2025-09-30 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-01 2025-12-31 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2025-12-31 0001938046 us-gaap:SeriesAPreferredStockMember 2025-01-09 0001938046 us-gaap:SeriesAPreferredStockMember 2025-01-09 2025-01-09 0001938046 MGRX:JacobCohenMember 2025-01-30 2025-01-30 0001938046 us-gaap:SeriesBPreferredStockMember 2025-01-15 2025-01-15 0001938046 MGRX:AmendmentLetterMember 2026-03-31 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-02-12 2025-02-12 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-02-12 0001938046 MGRX:SeriesBDesignationMember MGRX:SeriesBConvertiblePreferredStockDesignationMember 2025-03-17 2025-03-17 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-04-03 2025-04-03 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-04-03 0001938046 MGRX:SeriesBConvertiblePreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2025-04-11 2025-04-11 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-04-28 2025-04-28 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-04-28 0001938046 us-gaap:SeriesBPreferredStockMember 2025-05-01 2025-05-01 0001938046 us-gaap:SeriesBPreferredStockMember 2025-05-01 0001938046 MGRX:JacobCohenMember us-gaap:CommonStockMember 2025-05-13 2025-05-13 0001938046 MGRX:JacobCohenMember us-gaap:PreferredStockMember 2025-05-13 2025-05-13 0001938046 MGRX:JacobCohenMember us-gaap:CommonStockMember 2025-05-13 0001938046 MGRX:JacobCohenMember 2025-05-13 2025-05-13 0001938046 MGRX:ClarificationAgreementMember 2026-05-18 2026-05-18 0001938046 MGRX:ClarificationAgreementMember 2026-05-18 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-06-05 2025-06-05 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-06-05 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-09-16 2025-09-16 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-09-16 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-10-16 2025-10-16 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-10-16 0001938046 2025-12-18 2025-12-18 0001938046 2025-12-18 0001938046 2025-12-24 0001938046 us-gaap:PrivatePlacementMember 2025-12-24 2025-12-24 0001938046 us-gaap:WarrantMember us-gaap:IPOMember 2025-12-24 2025-12-24 0001938046 MGRX:MangoRxMexicoMember 2025-12-31 0001938046 MGRX:MangoRxUKLimitedMember 2025-12-31 0001938046 MGRX:MangoAndPeachesMember 2025-12-31 0001938046 MGRX:MangoRxIPHoldingsLLCMember 2025-12-31 0001938046 MGRX:MangoRxMexicoMember 2024-12-13 0001938046 MGRX:MangoRxUKLimitedMember 2024-12-13 0001938046 MGRX:MangoRxMexicoMember 2026-03-31 0001938046 MGRX:ThirdPartiesMember 2026-03-31 0001938046 MGRX:MangoAndPeachesCorpMember 2026-03-31 0001938046 MGRX:MangoAndPeachesCorpMember 2026-03-31 0001938046 MGRX:MAndPandMrCohenMember 2026-03-31 0001938046 srt:MinimumMember us-gaap:PatentsMember 2026-03-31 0001938046 srt:MaximumMember us-gaap:PatentsMember 2026-03-31 0001938046 us-gaap:PatentsMember 2026-01-01 2026-03-31 0001938046 MGRX:PropreEnergieIncMember MGRX:MasterDistributionAgreementMember 2025-01-30 2025-01-30 0001938046 MGRX:PropreEnergieIncMember MGRX:MasterDistributionAgreementMember 2025-01-30 0001938046 MGRX:MasterDistributionAgreementMember 2026-01-01 2026-03-31 0001938046 MGRX:MasterDistributionAgreementMember 2025-01-01 2025-12-31 0001938046 MGRX:OptionsMember 2026-01-01 2026-03-31 0001938046 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001938046 us-gaap:DerivativeMember 2026-01-01 2026-03-31 0001938046 MGRX:OptionsMember 2025-01-01 2025-03-31 0001938046 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001938046 us-gaap:DerivativeMember 2025-01-01 2025-03-31 0001938046 srt:MinimumMember 2026-03-31 0001938046 srt:MaximumMember 2026-03-31 0001938046 us-gaap:PatentsMember 2026-03-31 0001938046 MGRX:MasterDistributionAgreementMember 2026-03-31 0001938046 MGRX:PeriodEndSpotRateMember 2026-03-31 0001938046 country:MX MGRX:PeriodEndSpotRateMember 2026-03-31 0001938046 MGRX:PeriodEndSpotRateMember 2025-12-31 0001938046 country:MX MGRX:PeriodEndSpotRateMember 2025-12-31 0001938046 MGRX:AverageRateMember 2026-03-31 0001938046 country:MX MGRX:AverageRateMember 2026-03-31 0001938046 MGRX:AverageRateMember 2025-12-31 0001938046 country:MX MGRX:AverageRateMember 2025-12-31 0001938046 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001938046 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001938046 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001938046 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001938046 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001938046 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001938046 MGRX:ComputersMember 2026-03-31 0001938046 MGRX:ComputersMember 2025-12-31 0001938046 us-gaap:EquipmentMember 2026-03-31 0001938046 us-gaap:EquipmentMember 2025-12-31 0001938046 2022-10-01 0001938046 2025-11-01 0001938046 MGRX:LeaseTwoMember 2026-03-31 0001938046 MGRX:LeaseTwoMember 2025-12-31 0001938046 2025-09-01 0001938046 MGRX:LeaseThreeMember 2026-03-31 0001938046 MGRX:LeaseThreeMember 2025-12-31 0001938046 MGRX:CohenEnterprisesIncMember 2024-10-18 0001938046 MGRX:CohenEnterprisesIncMember 2024-03-18 0001938046 MGRX:CohenEnterprisesIncMember 2024-04-01 0001938046 MGRX:CohenEnterprisesIncMember 2024-12-13 2024-12-13 0001938046 MGRX:TheTigerCubTrustMember 2025-05-02 0001938046 MGRX:TheTigerCubTrustMember 2025-05-02 2025-05-02 0001938046 MGRX:TheTigerCubTrustMember 2025-12-19 2025-12-19 0001938046 MGRX:TheTigerCubTrustMember 2026-01-01 2026-03-31 0001938046 MGRX:TheTigerCubTrustMember 2025-07-31 0001938046 MGRX:TheTigerCubTrustMember 2025-07-21 2025-07-21 0001938046 MGRX:TheTigerCubTrustMember 2026-03-31 0001938046 MGRX:TheTigerCubTrustMember 2025-07-21 0001938046 MGRX:TheTigerCubTrustMember 2025-12-04 0001938046 MGRX:TheTigerCubTrustMember 2025-12-19 0001938046 MGRX:MillEndCapitalLtdMember MGRX:CohenEnterprisesIncMember 2024-12-13 0001938046 MGRX:DebtConversionAgreementMember MGRX:MillEndCapitalLtdMember 2024-12-13 0001938046 MGRX:DebtConversionAgreementMember MGRX:MillEndCapitalLtdMember 2025-01-15 0001938046 MGRX:DebtConversionAgreementMember MGRX:MillEndCapitalLtdMember 2025-01-15 2025-01-15 0001938046 MGRX:IndigoCapitalLPMember 2025-04-15 0001938046 MGRX:IndigoCapitalLPMember 2025-04-15 2025-04-15 0001938046 us-gaap:WarrantMember MGRX:AgreementToAmendMember 2025-05-27 0001938046 MGRX:AmendedAndRestatedPromissoryNoteMember us-gaap:CommonStockMember 2025-05-27 0001938046 MGRX:AmendedAndRestatedPromissoryNoteMember us-gaap:CommonStockMember 2025-05-27 2025-05-27 0001938046 MGRX:AmendedAndRestatedPromissoryNoteMember us-gaap:WarrantMember 2025-05-27 0001938046 MGRX:AmendedAndRestatedPromissoryNoteMember us-gaap:WarrantMember 2025-05-27 2025-05-27 0001938046 MGRX:IndigoCapitalLPMember 2025-07-16 0001938046 MGRX:IndigoCapitalLPMember 2025-07-16 2025-07-16 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2024-03-28 0001938046 2024-03-28 0001938046 us-gaap:SeriesBPreferredStockMember 2026-03-31 0001938046 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-06 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-03-25 2025-03-25 0001938046 MGRX:SeriesBConvertiblePreferredStockOneMember 2025-03-25 0001938046 MGRX:SeriesBConvertiblePreferredStockOneMember 2025-03-25 2025-03-25 0001938046 MGRX:SeriesBConvertiblePreferredStockTwoMember 2025-03-25 2025-03-25 0001938046 MGRX:SeriesBConvertiblePreferredStockTwoMember 2025-03-25 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-03-26 2025-03-26 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-03-26 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-03-28 2025-03-28 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-03-28 0001938046 MGRX:SeriesBConvertiblePreferredStockOneMember 2025-03-28 2025-03-28 0001938046 MGRX:SeriesBConvertiblePreferredStockOneMember 2025-03-28 0001938046 MGRX:SeriesBConvertiblePreferredStockTwoMember 2025-03-28 2025-03-28 0001938046 MGRX:SeriesBConvertiblePreferredStockTwoMember 2025-03-28 0001938046 MGRX:SeriesBConvertiblePreferredStockDesignationMember 2025-03-17 2025-03-17 0001938046 us-gaap:SeriesBPreferredStockMember 2025-04-03 2025-04-03 0001938046 us-gaap:SeriesBPreferredStockMember 2025-04-03 0001938046 us-gaap:SeriesBPreferredStockMember 2025-04-28 2025-04-28 0001938046 us-gaap:SeriesBPreferredStockMember 2025-04-28 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-05-01 2025-05-01 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2025-05-01 0001938046 us-gaap:SeriesBPreferredStockMember 2025-06-05 2025-06-05 0001938046 us-gaap:SeriesBPreferredStockMember 2025-06-05 0001938046 us-gaap:SeriesBPreferredStockMember 2025-09-15 2025-09-15 0001938046 us-gaap:SeriesBPreferredStockMember 2025-09-15 0001938046 us-gaap:SeriesBPreferredStockMember 2025-10-16 2025-10-16 0001938046 us-gaap:SeriesBPreferredStockMember 2025-10-16 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2024-04-18 2024-04-18 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2024-04-18 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2026-03-31 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2025-12-31 0001938046 us-gaap:SeriesCPreferredStockMember 2024-04-18 0001938046 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-03-31 0001938046 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-12-31 0001938046 MGRX:IPPurchaseAgreementMember 2024-04-24 2024-04-24 0001938046 us-gaap:SeriesCPreferredStockMember MGRX:IPPurchaseAgreementMember 2024-04-24 2024-04-24 0001938046 us-gaap:SeriesCPreferredStockMember MGRX:IPPurchaseAgreementMember 2024-04-24 0001938046 MGRX:IPPurchaseAgreementMember 2024-01-01 2024-12-31 0001938046 MGRX:ConsultingAgreementMember MGRX:LSTMHoldingsLLCMember 2026-01-01 2026-01-01 0001938046 MGRX:ConsultingAgreementLSTMMember 2026-01-01 2026-12-31 0001938046 MGRX:ConsultingAgreementMember MGRX:LSTMHoldingsLLCMember 2026-01-01 0001938046 MGRX:ConsultingAgreementLSTMMember 2026-01-01 2026-01-01 0001938046 MGRX:ConsultingAgreementLSTMMember 2026-01-12 2026-01-12 0001938046 MGRX:ConsultingAgreementLSTMMember 2026-03-16 0001938046 MGRX:ConsultingAgreementMember MGRX:LSTMHoldingsLLCMember 2026-01-22 0001938046 2026-01-22 2026-01-22 0001938046 MGRX:ConsultingAgreementMuhammadAzfarMember 2026-01-22 0001938046 MGRX:ConsultingAgreementMuhammadAzfarMember 2026-01-01 0001938046 MGRX:ConsultingAgreementMuhammadAzfarMember 2026-01-22 2026-01-22 0001938046 MGRX:ConsultingAgreementMuhammadAzfarMember 2026-03-13 0001938046 MGRX:ConsultingAgreementMuhammadAzfarMember 2026-03-13 2026-03-13 0001938046 MGRX:ConsultingAgreementMember MGRX:GatorlandHoldingsLlcMember 2026-03-16 0001938046 MGRX:ConsultingAgreementMuhammadAzfarMember 2026-03-16 0001938046 MGRX:ConsultingAgreementMuhammadAzfarMember 2026-03-16 2026-03-16 0001938046 MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2022-01-01 2022-12-31 0001938046 srt:ChiefExecutiveOfficerMember MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2022-01-01 2022-12-31 0001938046 srt:ChiefOperatingOfficerMember MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2022-01-01 2022-12-31 0001938046 srt:ChiefOperatingOfficerMember MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2023-05-01 2023-05-01 0001938046 srt:ChiefExecutiveOfficerMember MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2023-12-28 2023-12-28 0001938046 MGRX:JohnathanArangoMember 2024-03-28 2024-03-28 0001938046 MGRX:JohnathanArangoMember 2024-06-28 2024-06-28 0001938046 MGRX:RaffiSahulMember MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2024-07-12 2024-07-12 0001938046 MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-09-09 2025-09-09 0001938046 srt:ChiefExecutiveOfficerMember MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-09-09 2025-09-09 0001938046 2026-03-16 2026-03-16 0001938046 MGRX:MrJacobCohenMember us-gaap:CommonStockMember 2022-08-31 0001938046 MGRX:MrJacobCohenMember us-gaap:CommonStockMember 2022-08-31 2022-08-31 0001938046 MGRX:MrCohenMember us-gaap:CommonStockMember 2023-12-28 0001938046 MGRX:MrCohenMember us-gaap:CommonStockMember 2023-12-28 2023-12-28 0001938046 MGRX:MrCohenMember us-gaap:CommonStockMember 2025-09-09 0001938046 MGRX:MrCohenMember us-gaap:CommonStockMember 2025-09-09 2025-09-09 0001938046 2025-01-01 2025-12-31 0001938046 MGRX:RangeOneMember 2026-03-31 0001938046 MGRX:RangeOneMember 2026-01-01 2026-03-31 0001938046 MGRX:RangeTwoMember 2026-03-31 0001938046 MGRX:RangeTwoMember 2026-01-01 2026-03-31 0001938046 MGRX:RangeThreeMember 2026-03-31 0001938046 MGRX:RangeThreeMember 2026-01-01 2026-03-31 0001938046 MGRX:RangeFourMember 2026-03-31 0001938046 MGRX:RangeFourMember 2026-01-01 2026-03-31 0001938046 MGRX:RangeFiveMember 2026-03-31 0001938046 MGRX:RangeFiveMember 2026-01-01 2026-03-31 0001938046 srt:MaximumMember 2026-01-01 2026-03-31 0001938046 srt:MinimumMember 2026-01-01 2026-03-31 0001938046 MGRX:PrivatePlacementWarrantMember 2022-08-31 0001938046 MGRX:TwentyThreeAccreditedInvestorsMember MGRX:PrivatePlacementWarrantMember 2022-08-16 2022-12-22 0001938046 MGRX:PrivatePlacementWarrantMember 2026-03-31 0001938046 MGRX:PrivatePlacementWarrantMember 2025-12-31 0001938046 us-gaap:WarrantMember us-gaap:IPOMember 2023-03-20 0001938046 us-gaap:WarrantMember us-gaap:IPOMember 2023-03-19 2023-03-20 0001938046 us-gaap:CommonStockMember us-gaap:IPOMember 2023-12-19 0001938046 us-gaap:CommonStockMember us-gaap:IPOMember 2023-12-19 2023-12-19 0001938046 us-gaap:WarrantMember MGRX:UnderwritingAgreementMember 2024-01-22 0001938046 MGRX:UnderwritingAgreementMember 2024-01-22 2024-01-22 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-04 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-04 2024-04-04 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 2024-06-28 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 0001938046 MGRX:WarrantOneMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 2024-06-28 0001938046 MGRX:WarrantOneMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 0001938046 MGRX:ConsultingAgreementMember MGRX:LevoHealthcareConsultingIncMember 2024-08-22 0001938046 us-gaap:RestrictedStockMember MGRX:ConsultingAgreementMember MGRX:LevoHealthcareConsultingIncMember 2024-08-22 2024-08-22 0001938046 us-gaap:RestrictedStockMember MGRX:ConsultingAgreementMember MGRX:LevoHealthcareConsultingIncMember 2024-08-22 0001938046 MGRX:CommonStockPurchaseWarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-12-18 2024-12-31 0001938046 MGRX:CommonStockPurchaseWarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-12-31 0001938046 us-gaap:SeriesBPreferredStockMember 2025-01-03 2025-01-03 0001938046 us-gaap:CommonStockMember 2025-01-03 0001938046 us-gaap:SeriesBPreferredStockMember 2025-01-06 2025-01-06 0001938046 us-gaap:CommonStockMember 2025-01-06 0001938046 us-gaap:CommonStockMember MGRX:SecuritiesPurchaseAgreementMember 2025-01-06 0001938046 2025-01-06 2025-01-06 0001938046 us-gaap:CommonStockMember 2025-02-10 0001938046 us-gaap:CommonStockMember 2025-02-11 2025-02-11 0001938046 MGRX:CommonStockOneMember 2025-02-11 0001938046 MGRX:CommonStockOneMember 2025-02-11 2025-02-11 0001938046 MGRX:CommonStockThreeMember 2025-02-14 0001938046 MGRX:CommonStockThreeMember 2025-02-14 2025-02-14 0001938046 us-gaap:WarrantMember 2025-06-02 2025-06-02 0001938046 us-gaap:CommonStockMember 2025-06-02 2025-06-02 0001938046 2025-06-02 0001938046 us-gaap:WarrantMember 2025-06-02 0001938046 2025-06-02 2025-06-02 0001938046 us-gaap:WarrantMember MGRX:WarrantHolderMember 2025-06-02 2025-06-02 0001938046 MGRX:WarrantHolderMember 2025-06-02 0001938046 srt:MaximumMember 2025-06-02 2025-06-02 0001938046 2025-06-09 0001938046 2025-06-09 2025-06-09 0001938046 2025-07-29 0001938046 2025-07-29 2025-07-29 0001938046 2025-12-19 2025-12-19 0001938046 2025-12-19 0001938046 2025-12-24 2025-12-24 0001938046 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001938046 srt:MinimumMember us-gaap:WarrantMember 2026-03-31 0001938046 srt:MaximumMember us-gaap:WarrantMember 2026-03-31 0001938046 srt:MinimumMember us-gaap:WarrantMember 2026-01-01 2026-03-31 0001938046 srt:MaximumMember us-gaap:WarrantMember 2026-01-01 2026-03-31 0001938046 2025-06-23 2025-06-23 0001938046 MGRX:BousteadAgreementMember 2025-02-18 0001938046 MGRX:CompromiseSettlementAgreementAndMutualReleaseMember 2025-05-05 2025-05-05 0001938046 MGRX:IsaacConsultingAgreementMember 2025-01-15 2025-01-15 0001938046 2025-01-27 0001938046 2025-08-06 2025-08-06 0001938046 2026-01-01 0001938046 MGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember MGRX:MangoAndPeachesMember 2025-04-24 2025-04-24 0001938046 srt:MaximumMember MGRX:MrCohenMember MGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember 2025-04-24 2025-04-24 0001938046 srt:MinimumMember MGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember MGRX:MangoAndPeachesMember 2025-04-24 2025-04-24 0001938046 srt:MinimumMember MGRX:MrCohenMember MGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember 2025-04-24 2025-04-24 0001938046 MGRX:MrCohenMember MGRX:AmendedAndRestatedExecutiveEmploymentAgreementMember 2026-03-31 0001938046 srt:ChiefFinancialOfficerMember 2026-03-20 2026-03-20 0001938046 srt:MaximumMember srt:ChiefFinancialOfficerMember 2026-03-20 2026-03-20 0001938046 2025-05-14 2025-05-14 0001938046 MGRX:PremisesMember MGRX:SVHQLLCMember 2025-11-01 0001938046 MGRX:SharedSpaceMember MGRX:SVHQLLCMember 2025-11-01 0001938046 MGRX:SVHQLLCMember 2025-11-01 2025-11-01 0001938046 MGRX:SVHQLLCMember 2025-11-01 0001938046 MGRX:PremisesMember MGRX:SVHQLLCMember 2025-11-01 2025-11-01 0001938046 MGRX:SharedSpaceMember MGRX:SVHQLLCMember 2025-11-01 2025-11-01 0001938046 MGRX:SVHQLLCMember 2022-09-28 0001938046 MGRX:SVHQLLCMember 2026-03-31 0001938046 MGRX:SVHQLLCMember 2026-01-01 2026-03-31 0001938046 2025-09-30 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember 2026-04-27 2026-04-27 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember 2026-04-27 0001938046 us-gaap:SubsequentEventMember MGRX:ClarificationAgreementMember 2026-05-18 2026-05-18 iso4217:USD shares iso4217:USD shares pure utr:sqft false Q1 --12-31 0001938046

10-Q true 2026-03-31 2026 false 001-41615 Mangoceuticals, Inc. TX 87-3841292 17130 N. Dallas Parkway Suite 240 Dallas TX 75248 (214) 242-9619 Common Stock, par value $0.0001 per share MGRX NASDAQ Yes Yes Non-accelerated Filer true true false false 17167422

174562

1486338

897

7021

120

16957

33899

20056

212472

1547434

3518

3268

1544

1794

294061

307861

13941146

14232484

14236751

14542139

14449223

16089573

529800

416682

3297

9421

57058

307823

147451

156642

147451

156642

737606

890568

236965

974571

890568

0.0001

6000

0.0001

6250000

980000

0.0001

200000000

16967421

15888795

1698

1589

324288 324288

57203924

55524812

-44050630

-40647480

-3193

-2760

13476185

15200547

-1533

-1542

13474652

15199005

14449223

16089573

67864

109306

8218

24737

30645

22505

29001

62064

1054122

1542444

346860

349783

94073

281732

12451 1419000

1647821

1045479

3155327

4638438

-3126326

-4576374

-13700

276815

-276815

-263115

-3403141

-4839489

-3403141

-4839489

-98

-3403150

-4839391

-0.22

-1.12

16481607

4593062

294000

-3697150

-5133391

-3403141

-4839489

-3193

7624

-3406334

-4831865

-1533

-98

-3404801

-4831767

2770

980000

3245641

325

324288

-1150000

34785749

-20004486

-9845

-1081

13945048

1150000 1150000

522000

1938448

1938500

305555

654969

655000

320000

479968

480000

1650000 165 6712835 6713000 100000 10 149990 150000

-1438

-1581812

1001734

100

1581712

1581812

50979

7624

-4839391

-98

-4839489

1332

980000

7144930

715

324288

44772837

-24843877

-2221

-1179

20250661

980000

15888796

1589

324288

55524812

-40647480

-2760

-1542

15199005

980000

15888796

1589

324288

55524812

-40647480

-2760

-1542

15199005

1078625

109

588998

589107

1090114

-433

-3403150

-3403141

980000

16967421

1698

324288

57203924

-44050630

-3193

-1533

13474652

980000

16967421

1698

324288

57203924

-44050630

-3193

-1533

13474652

-3403141

-4839489

250

589107

1938500

1090114

50979

276815

14523 137927 13800 15719

-120

-6124

83214

16942

113118

340678

-13800

-17249

-6124

-9191

-121576

25879

-1311343

-2274781

655000

1150000

480000

2285000

-1311343

10219

1486338

58653

-433

7624

174562

76496

6713000 294000 150000 1581812

<p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zIEhhCD7B42i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS Mangoceuticals, Inc. (“Mangoceuticals” or the “Company”), was incorporated in the State of a Texas on October 7, 2021, with the intent of focusing on developing, marketing, and selling a variety of men’s wellness products and services via a telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector in the most recent years and especially related to the areas of erectile dysfunction (“ED”), hair loss, testosterone replacement or enhancement therapies, and weight management treatments. In this regard, we have developed and are commercially marketing a brand of ED products under the brand name “Mango,” a brand of hair loss products under the brand name “Grow,” a brand of hormone balance and therapy products under the name “Mojo,” and a brand of weight loss products under the brand name “Slim” (Mango, Grow, Mojo, and Slim are collectively referred to as the “Compounded Products”). The Company is also marketing and selling an U.S. Food and Drug Administration (“FDA”) approved form of oral testosterone undecanoate to treat low testosterone in men and as a form of Testosterone Replacement Therapy (TRT), developed and produced by Marius Pharmaceuticals, Inc. under the brand name “Prime” powered by Kyzatrex® (“Prime”) (Prime and our Compounded Products collectively referred to as the “Pharmaceutical Products”). The Company, through the patent portfolio acquired as part of the Intramont IP Purchase Agreement (as further described below), is in the process of conducting Phase II clinical trials and efficacy studies to determine the effectiveness of its patented respiratory illness prevention technology against the likes of the influenza A virus (H1N1) and avian influenza (H5N1). A majority of these studies were completed in 2025 and the Company is currently in the process of determining next steps in its commercialization and monetization efforts. The Company, through its Master Distribution Agreement with Propre Energie, Inc. (as further described below) intends to license certain intellectual property and patent rights from Propre relating to clinically proven, plant-based formulations targeting hyperpigmentation, dark spots, uneven skin tone, and skin brightening through advanced solutions marketed under the brand Dermytol® (“Dermytol”). The Company is in the process of preparing its marketing and distribution strategy for Dermytol and intends to commence operations under this agreement in the 1st quarter of 2026. The Company’s Compounded Products are produced at and fulfilled by a related party compounding pharmacy using a proprietary combination of FDA approved ingredients which are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mangoceuticals is currently marketing and selling the Pharmaceutical Products exclusively online via its website at www.MangoRx.com. Product availability varies by state with additional details available on our website. Initial Public Offering. In March 2023, the Company completed an initial public offering (the “IPO”), in which the Company issued and sold 83,333 shares of common stock for $60.00 per share for net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn4n6_c20230301__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2MHejyRdxNe" title="Net proceeds from initial public offering">4.35 million, after deducting underwriting discounts and commissions, and offering costs. At the same time, and as part of the same registration statement, but pursuant to a separate prospectus (the “Resale Prospectus”) the Company registered the sale of 317,667 shares of common stock, including <span id="xdx_906_ecustom--SharesIssuableUponExerciseOfWarrants_iI_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zUzaBxU5p1lf" title="Shares issuable upon exercise of warrants">133,333 shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with an exercise price of $15.00 per share. Effective on January 3rd and 6th, 2025, we agreed to definitive terms on Securities Purchase Agreements (the “January 2025 SPAs”), with certain institutional accredited investors (the “January Purchasers”), pursuant to which the Company sold the January Purchasers, and the January Purchasers purchased from the Company, <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250103__20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zAfKZJkMoasj" title="Number of shares sold">300 shares of Series B Preferred Stock for $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250103__20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqVTVVwR0jXl" title="Value of shares sold">300,000, and warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQwNTUBqWQ4h" title="Warrants to purchase common stock">396,000 shares of common stock with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRrMc6hQ9kLe" title="Warrant exercise price">2.61 per share; <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPd1ZcoJ9s1g" title="Number of shares sold">500 shares of Series B Preferred Stock for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmpTl84HCxo5" title="Value of shares sold">500,000, and warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuncNWrHrGgd" title="Warrants to purchase common stock">660,000 shares of common stock with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOpVccBMmfml" title="Warrant exercise price">2.59 per share; and <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7pGecBffLWa" title="Number of shares sold">50 shares of Series B Preferred Stock for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zm1iXwN3fvw6" title="Value of shares sold">50,000, and warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKLs3NDLX19c" title="Warrants to purchase common stock">66,000 shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjwObh0oNxVd" title="Warrant exercise price">2.59 per share, respectively. Each of the January 2025 SPAs closed on the dates they were entered into, and the warrants were granted on the same dates. On January 9, 2025, our subsidiary Mango & Peaches Corp. filed a Certificate of Designations of Mango & Peaches Corp. (“Mango & Peaches”), establishing the designations, preferences, limitations, and relative rights of its Series A Super Majority Voting Preferred Stock (the “Series A Preferred Stock”), with the Secretary of State of Texas, which was filed by the Texas Secretary of State on January 15, 2025, effective January 9, 2025 (the “Series A Designation”). The Series A Designation designated 100 shares of Series A Preferred Stock. The Series A Designation provides for the Series A Preferred Stock to have the following rights: No dividend, liquidation, redemption or conversion rights; voting rights providing that for so long as any shares of Series A Preferred Stock remain issued and outstanding, the holders thereof, voting separately as a class, have the right to vote on all shareholder matters (including, but not limited to at every meeting of the stockholders of Mango & Peaches and upon any action taken by stockholders of Mango & Peaches with or without a meeting) equal to fifty-one percent (51%) of the total vote (the “Total Series A Vote” and the “Voting Rights”), and that so long as Series A Preferred Stock is outstanding, Mango & Peaches shall not, without the affirmative vote of the holders of at least 66-2/3% of all outstanding shares of Series A Preferred Stock, voting separately as a class (i) amend, alter or repeal any provision of the Certificate of Formation or the Bylaws of Mango & Peaches so as to adversely affect the designations, preferences, limitations and relative rights of the Series A Preferred Stock, (ii) effect any reclassification of the Series A Preferred Stock, (iii) designate any additional series of preferred stock, the designation of which adversely affects the rights, privileges, preferences or limitations of the Series A Preferred Stock; or (iv) amend, alter or repeal any provision of the Series A Designation (except in connection with certain non-material technical amendments). Additionally, subject to the rights of series of preferred stock which may from time to time come into existence, so long as any shares of Series A Preferred Stock are outstanding, Mango & Peaches cannot without first obtaining the approval (by written consent, as provided by law) of the holders of a majority of the then outstanding shares of Series A Preferred Stock, voting together as a class: (a) issue any additional shares of Series A Preferred Stock after the original issuance of shares of Series A Preferred Stock; (b) increase or decrease the total number of authorized or designated shares of Series A Preferred Stock; (c) effect an exchange, reclassification, or cancellation of all or a part of the Series A Preferred Stock; (d) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series A Preferred Stock; or (e) alter or change the rights, preferences or privileges of the shares of Series A Preferred Stock so as to affect adversely the shares of such series, including the rights set forth in the Series A Designation. On January 30, 2025, the Company, with the approval of the disinterested members of the Board of Directors and the Company’s Audit Committee, made up of independent members of the Board of Directors, entered into two Assignment, Assumption and Novation Agreements (the “Epiq Scripts Assignments”) with Epiq Scripts, LLC, which is 52% owned by Jacob Cohen, the Company’s Chief Executive Officer and Chairman, and the Chief Executive Officer and sole director of Mango & Peaches, the Company’s then wholly-owned subsidiary (provided that the Company has agreed to issue Mr. Cohen <span id="xdx_905_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20250130__20250130__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JacobCohenMember_z7K78ardgXvl" title="Issuance of shares, description">(a) 4,892,906 shares of the common stock of Mango & Peaches (representing 49.0% of Mango & Peaches’s outstanding shares of common stock); and (b) 100 shares of Series A Super Majority Voting Preferred Stock of Mango & Peaches, which will have the right to vote fifty-one percent (51%) of the total vote on all Mango & Peaches shareholder matters). Pursuant to the Epiq Scripts Assignments, the Company assigned all of its rights under (1) a September 1, 2022, Master Services Agreement, as amended with Epiq Scripts; and (2) a September 15, 2023, Consulting Agreement with Epiq Scripts, to Mango & Peaches, Mango & Peaches agreed to take responsibility for all obligations thereunder, effective as of the assignment date, and Epiq Scripts agreed to novate the responsibility of the Company thereunder, effective as of the assignment date. Additionally, we agreed to indemnify Mango & Peaches for any liability under such agreements prior to the assignment date and Mango & Peaches agreed to indemnify us against any liability under such agreements after the assignment date. On January 15, 2025, the Company sold the Purchaser the final <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250115__20250115__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNkzPjH4fomd" title="Number of shares sold">250 shares of Series B Preferred Stock (the “Final Fourth Closing Shares”) for $250,000 in connection with a partial and final closing of the Fourth Closing. On February 11, 2025, and effective on December 31, 2024, we and Intramont entered into a letter agreement, amending the Intramont IP Purchase Agreement (the “Amendment Letter”), pursuant to which Intramont has agreed that all funds paid by the Company towards the furtherance and development of the Patents would be credited against the Cash Payments owed to Intramont and we agreed to work in good faith with Intramont on financing, developing and commercializing the Patents. As a result of the Amendment Letter, as of March 31, 2026, a total of $147,451 remains due to Intramont in connection with the Cash Payments, which the Company expects to pay over time, by way of expenses associated with the development of the Patents. On February 12, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted 216 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span id="xdx_904_eus-gaap--ConversionOfStockAmountConverted1_c20250212__20250212__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zJaXaHXTU4Ld" title="Aggregrate stated value">237,600) into 105,600 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250212__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z1sDwf252Ii5" title="Preferred stock, convertible, conversion price">2.25 per share. On March 17, 2025, with the approval of the shareholders of the Company at the special meeting of shareholders held on the same date, the Company submitted to the Secretary of the State of Texas, an amendment to the Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc. (the “Series B Designation”), to: <span id="xdx_900_eus-gaap--CommonStockConversionFeatures_c20250317__20250317__us-gaap--TypeOfArrangementAxis__custom--SeriesBConvertiblePreferredStockDesignationMember__us-gaap--AwardTypeAxis__custom--SeriesBDesignationMember_z77jJNHkAp7j">(a) reduce the conversion price set forth therein to a fixed price of $1.50 per share (subject to customary adjustments for stock splits) (compared to having a fixed conversion price of $2.25 prior to the amendment)(the “Conversion Price”); (b) reduce the floor price set forth therein from $2.25 to $1.50 per share (subject to customary adjustments for stock splits)(the “Floor Price”); (c) remove the dividend rights set forth therein (except for standard participatory rights for dividends declared on the Company’s common stock); and exclude the Company’s then wholly-owned subsidiary, Mango & Peaches Corp. (“Mango & Peaches”), from the definition of Change of Control Transaction thereunder (as a result, the issuance of securities of Mango & Peaches to Mr. Jacob Cohen, the Company’s Chief Executive Officer and Chairman, will not be a Change of Control Transaction, trigger an event of default under the Series B Preferred Stock or be deemed an Equity Condition (as defined in the designation of the Series B Preferred Stock)(the “Designation Amendment”). On April 3, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20250403__20250403__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zcbkc0jfDgKi" title="Conversion of share">350 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span id="xdx_902_eus-gaap--ConversionOfStockAmountConverted1_c20250403__20250403__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zU3pwv16fkKb" title="Aggregrate stated value">385,000) into 256,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250403__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zpT1YMUw4jq2" title="Preferred stock, convertible, conversion price">1.50 per share. On April 11, 2025, the Company agreed to definitive terms on a Securities Purchase Agreement with an institutional accredited investor pursuant to which the Company sold the purchaser, and the purchaser purchased from the Company <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250411__20250411__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zF4LO6pkmEF" title="Number of shares sold">100 shares of Series B Convertible Preferred Stock of the Company for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250411__20250411__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5C7zGQHSlI1" title="Value of shares purchased">100,000. On April 28, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20250428__20250428__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zSx3MCe2NT1k" title="Conversion of share">100 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span id="xdx_90D_eus-gaap--ConversionOfStockAmountConverted1_c20250428__20250428__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zfFsPz5BpVg9" title="Aggregrate stated value">110,000) into 73,333 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250428__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zpTij9QEtup7" title="Preferred stock, convertible, conversion price">1.50 per share. On May 1, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted 300 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $330,000) into 220,000 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250501__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOIkg0CWnDe7" title="Preferred stock, convertible, conversion price">1.50 per share. If the Company or any subsidiary at any time while the warrants are outstanding, shall sell, enter into an agreement to sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any common stock or common stock equivalents, at an effective price per share less than the exercise price of the warrants then in effect (such lower price, the “Base Share Price” and such issuances collectively, a “Dilutive Issuance”) then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance the exercise price shall be reduced and only reduced to equal the Base Share Price. No adjustment, however, is to be made for certain customary Exempt Issuances (as defined in the SPAs). On May 13, 2025, Mango & Peaches, the Company’s then wholly-owned subsidiary issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250513__20250513__srt--TitleOfIndividualAxis__custom--JacobCohenMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfM3SqW2J267" title="Number of shares issued">4,892,906 shares of its common stock and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250513__20250513__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--TitleOfIndividualAxis__custom--JacobCohenMember_zmpjXS1uDPc9" title="Shares issued">100 shares of its Series A Super Majority Voting Preferred Stock (collectively, the “M&P Stock”) to Jacob Cohen, the Chief Executive Officer and Chairman of the Company and the Chief Executive Officer of Mango & Peaches, which was due pursuant to the terms of Mr. Cohen’s employment agreement with the Company, as amended. Following the issuance of the M&P Stock, Mr. Cohen owned <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_uPure_c20250513__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--OwnershipAxis__custom--JacobCohenMember_zKKuvcmJuvGb" title="Ownership percentage">49% of the outstanding common stock of Mango & Peaches and separately had the right to vote fifty-one percent (51%) of the total vote on all Mango & Peaches shareholder matters, voting separately as a class, pursuant to his ownership of the Series A Super Majority Voting Preferred Stock, giving him 75.2% voting control over Mango & Peaches. Notwithstanding this voting structure, Mr. Cohen serves simultaneously as Chief Executive Officer of Mangoceuticals, Inc., and the Company consolidates M&P on the basis of its 51% majority common stock ownership. See also the Clarification Agreement disclosure below. The Series A Super Majority Voting Preferred Stock carries no dividend rights, liquidation preference, conversion rights, or redemption rights. Its primary feature is its super majority voting power: while any Series A Super Majority Voting Preferred Stock shares remain outstanding, the holders collectively control 51% of the total shareholder vote of Mango & Peaches, regardless of the number of common shares outstanding (i.e., on a non-dilutive basis). Additionally, major corporate actions—such as amending governing documents, reclassifying the Series A Super Majority Voting Preferred Stock, or creating new classes of preferred stock that could affect the Series A Super Majority Voting Preferred Stock—require the approval of at least two-thirds of the Series A Super Majority Voting Preferred Stock holders. The designation also includes protective provisions preventing certain actions, such as issuing more Series A Super Majority Voting Preferred Stock or altering their rights, without majority consent from the Series A Super Majority Voting Preferred Stock holders. Clarification Agreement – Economic Rights of M&P Common Shares On May 18, 2026, M&P and Jacob Cohen, the Company’s Chief Executive Officer and Chairman, entered into a Clarification Agreement (the “Clarification Agreement”), effective as of May 13, 2025 (the date the M&P shares were originally issued to Mr. Cohen), clarifying the economic rights associated with the 4,892,906 shares of M&P common stock held by Mr. Cohen (the “Shares”). The Clarification Agreement confirms that it was never the intent of the parties that Mr. Cohen would participate in, bear responsibility for, or otherwise be allocated any losses, liabilities, negative capital accounts, deficits, indebtedness, obligations, or other negative economic attributes of M&P by virtue of his ownership of the Shares. The Clarification Agreement further confirms that Mr. Cohen retains the right to participate in positive economic value associated with the Shares, including any appreciation in value, dividends, distributions, sale proceeds, merger consideration, liquidation proceeds, or other economic benefits payable in respect of the Shares, subject to M&P’s organizational documents and applicable law. As of March 31, 2026, M&P has an accumulated deficit and no current positive equity value. Accordingly, no noncontrolling interest has been recognized in the condensed consolidated financial statements of the Company with respect to Mr. Cohen’s 49% interest in M&P, as any such balance is de minimis and immaterial. This conclusion will be reassessed in future periods. The Clarification Agreement was reviewed and approved by the disinterested members of the Board of Directors and the Audit Committee of the Board of Directors of the Company, comprised entirely of independent directors, in accordance with the Company’s related party transaction policies. See also Note 10 – Subsequent Events. On June 5, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20250605__20250605__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxi2IE6Tehm3" title="Conversion of share">100 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span id="xdx_904_eus-gaap--ConversionOfStockAmountConverted1_c20250605__20250605__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zLowaN2atk1i" title="Aggregrate stated value">110,000) into 73,333 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250605__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zjBsMHNVZj4e" title="Preferred stock, convertible, conversion price">1.50 per share. On September 16, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20250916__20250916__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zq6UsMjounS6" title="Number of shares converted">500 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span id="xdx_90F_eus-gaap--ConversionOfStockAmountConverted1_c20250916__20250916__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zOOtBThBX9Qh" title="Value of shares converted">550,000) into <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20250916__20250916__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z7zwxS2wynHc" title="Common stock issued upon share conversion">366,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250916__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zP6MW8VcEHwc" title="Preferred stock, conversion price">1.50 per share. On October 16, 2025, <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20251016__20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zwyooUx8gsnf" title="Number of shares converted">32 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span id="xdx_903_eus-gaap--ConversionOfStockAmountConverted1_c20251016__20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zk7INIap4NT9" title="Value of shares converted">35,200) were converted by the holder into <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20251016__20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zPVg5kjUXsaa" title="Common stock issued upon share conversion">23,467 shares of common stock at a conversion price of $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvsHP2utaDY1" title="Preferred stock, conversion price">1.50 per share. On December 18, 2025, the Company completed an offering of 1,430,502 shares of common stock at $1.295 per share and 500,000 pre-funded warrants at $1.29499 per warrant, with an exercise price of $0.000001, generating gross proceeds of $2,499,995. Offering costs totaled $285,000 for net funds to the Company of $2,224,995. On December 24, 2025, the 500,000 pre-funded warrants were fully exercised for $5 net of any expenses. The offering included a concurrent private placement for common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 1,930,502 shares of common stock, at an exercise price of $1.4245 per warrant share for aggregate gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20251224__20251224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyW0HMYXjLPi" title="Gross proceeds from offering costs">2.5 million, when exercised. MangoRx Mexico S.A. de C.V., a Mexican Stock Company, is <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxMexicoMember_zNCD9JzFuqDh" title="Equity ownership percentage">98% owned by Mango & Peaches Corp. (“MangoRx Mexico”) The entity was formed in September 2023 and has had limited operations since inception. MangoRx UK Limited, a company incorporated under the laws of the United Kingdom, is <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember_ztw9glzcKyMk" title="Equity ownership percentage">100% owned by Mango & Peaches Corp. The entity was formed in October 2023 and has had limited operations since inception. Mango & Peaches Corp., a company incorporated under the laws of Texas, is <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoAndPeachesMember_zzzpEPieBKRd" title="Equity ownership percentage">51% owned by Mangoceuticals, Inc. The entity was formed in December 2024. MangoRx IP Holdings, LLC, a Texas limited liability company is <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxIPHoldingsLLCMember_zTcEyJlZfY47" title="Equity ownership percentage">100% owned by Mangoceuticals, Inc. (“MangoRx IP”). The entity was formed on April 15, 2024 and has had limited operations since inception.

83333

60.00

4350000

317667

133333

15.00

300

300000

396000

2.61

500

500000

660000

2.59

50000

66000

2.59

100

equal to fifty-one percent (51%) of the total vote

(a) 4,892,906 shares of the common stock of Mango & Peaches (representing 49.0% of Mango & Peaches’s outstanding shares of common stock); and (b) 100 shares of Series A Super Majority Voting Preferred Stock of Mango & Peaches, which will have the right to vote fifty-one percent (51%) of the total vote on all Mango & Peaches shareholder matters).

250

250000

147451

216

237600

105600

2.25

(a) reduce the conversion price set forth therein to a fixed price of $1.50 per share (subject to customary adjustments for stock splits) (compared to having a fixed conversion price of $2.25 prior to the amendment)(the “Conversion Price”); (b) reduce the floor price set forth therein from $2.25 to $1.50 per share (subject to customary adjustments for stock splits)(the “Floor Price”); (c) remove the dividend rights set forth therein (except for standard participatory rights for dividends declared on the Company’s common stock)

350

385000

256667

1.50

100

100000

100

110000

73333

1.50

300

330000

220000

1.50

4892906

100

0.49

Series A Super Majority Voting Preferred Stock, giving him 75.2% voting control over Mango & Peaches

4892906

0.49

100

110000

73333

1.50

500

550000

366667

1.50

35200

23467

1.50

1430502

1.295

500000

1.29499

0.000001

2499995

285000

2224995

500000

1930502

1.4245

2500000

0.98

0.51

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations, and cash flows for the interim periods presented have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. The results for the three months ended March 31, 2026, are not necessarily indicative of the results to be expected for the full fiscal year. The condensed consolidated financial statements present the financial position, results of operations and cash flows of the Company in accordance with US GAAP. All dollar amounts are rounded to the nearest thousand dollars. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation on the condensed consolidated statements of operations. Prior period salary and benefits in the amount of $276,815, were reclassified to interest expense - amortization of intangible assets on the statement of operations. Cash and Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $250,000 per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, the excess would be at risk of loss for purposes of the statement of cash flows. There are no cash equivalents at March 31, 2026 and December 31, 2025. December 2024 Subsidiary Reorganization On December 13, 2024, the Company, entered into a Parent Subsidiary Contribution Agreement with Mango & Peaches Corp., a Texas corporation (“Mango & Peaches”), a then recently formed wholly-owned subsidiary of the Company (the “Contribution Agreement”). Pursuant to the Contribution Agreement, the Company contributed substantially all of its assets, including ownership of: (a) its <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20241213__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxMexicoMember_zGn3mparRoDk" title="Equity ownership percentage">98% ownership of MangoRx Mexico S.A. de C.V., a Mexican Stock Company; and (b) its <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20241213__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember_zw3brPX1VHgk" title="Equity ownership percentage">100% ownership of MangoRx UK Limited, a company incorporated under the laws of the United Kingdom (collectively, the “Contributed Assets”), to Mango & Peaches, in order to restructure the ownership and operations of the Company, better segregate such operations and liabilities and provided for the issuance of a portion of the capital of Mango & Peaches to Mr. Jacob Cohen, the Chief Executive Officer of the Company (the “Subsidiary Reorganization”). Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Mangoceuticals, Inc. and its consolidated subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Non-Controlling Interest The Company consolidates MangoRx Mexico S.A. de C.V., in which it holds a 98% ownership interest. The remaining 2% ownership interest held by third parties is presented as non-controlling interest, a separate component of stockholders’ equity in the accompanying consolidated balance sheets. The operations of MangoRx Mexico S.A. de C.V. are minimal, and the non-controlling interest balance and net income (loss) attributable to non-controlling interest for the periods presented are not material to the condensed consolidated financial statements. The Company also consolidates Mango & Peaches Corp. (“M&P”), in which it holds a <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoAndPeachesCorpMember_zc5Y6IWPnxEa" title="Equity ownership percentage">51% ownership interest based on majority voting interest. Jacob Cohen, the Company’s Chief Executive Officer and Chairman, holds the remaining 49% of M&P’s common stock. Pursuant to a Clarification Agreement entered into between M&P and Mr. Cohen, effective as of May 13, 2025 (the date the shares of M&P were originally issued to Mr. Cohen), Mr. Cohen’s 49% common stock interest in M&P carries no obligation to absorb losses, liabilities, deficits, or other negative economic attributes of M&P. Due to M&P’s accumulated deficit and the absence of current positive equity value, no noncontrolling interest has been recognized with respect to Mr. Cohen’s interest in M&P, as any such balance is de minimis and immaterial to the condensed consolidated financial statements. This conclusion will be reassessed in future periods. Segment Reporting The Company operates as a single operating segment. The Chief Decision-Making Officer (CDOM) reviews financial information on a consolidated basis for purposes of allocating resources and assessing performance. As such, the Company has determined that it operates in one reportable segment in accordance with Accounting Standards Codification (“ASC”) Topic 280, Segment Reporting. The Company’s operations are managed as a unified business, with consistent products and services offered across its customer base. The nature of the products and services, production processes, customer types, and distribution methods are substantially similar throughout the Company’s activities. All revenues, expenses, assets, and liabilities are evaluated collectively, and no discrete financial information is prepared or reviewed at a lower level. Accordingly, no additional segment information is presented Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes. Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740. ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Intangible Assets Patents The Company’s intangible assets consist of patents acquired through purchase, as described above. These patents are classified as finite-lived intangible assets and are amortized on a straight-line basis over their estimated useful lives, which range from <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_z2h4osEJ9xTi" title="Finite lived intangible assets, estimated useful lives years">14 to <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zdcWAQXyGV47" title="Finite-lived intangible assets, estimated useful lives">17 years. <p id="xdx_896_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znr55chgSuhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of patents as of March 31, 2026 is as follows: SCHEDULE OF CARRYING AMOUNT OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross carrying amount:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,954,150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated amortization:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zll2qw0Zwj21" title="Accumulated amortization">2,120,987</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,833,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuJ4nblNd1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Amortization expense for the three months ended March 31, 2026 was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zsH3SRdBiJX" title="Amortization expense">276,815. The estimated amortization expense for the next five years is as follows: SCHEDULE OF ESTIMATED AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Year 1:</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 16%"> <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2do6yf10lc7" title="Year 1">1,122,639</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year 2:</td> <td> </td> <td> </td> <td style="text-align: right"> <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zaPDVukHrLtl" title="Year 2">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year 3:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year 4:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year 5:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Thereafter:</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8bAKCjrCV5" title="Thereafter:">8,219,968</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total:</td> <td> </td> <td>$</td> <td style="text-align: right">13,833,163</td> <td> </td></tr> </table> The Company performs periodic impairment testing for its intangible assets to ensure that the carrying amount does not exceed the recoverable amount. For the three months ended March 31, 2026, no impairment losses were recognized. Master Distribution Agreements On January 30, 2025, the Company entered into a Master Distribution Agreement (“MDA”) with Propre Energie Inc., granting the Company a license to certain intellectual property and patent rights related to clinically proven plant-based formulations under the brand Dermytol®. These formulations target hyperpigmentation, dark spots, uneven skin tone, and skin brightening. As consideration, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20250130__20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_zbxVm72wgmqa" title="Common shares issued for consideration">650,000 common shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_z1aF8NBjkKl1" title="Common stock par value">0.0001 and a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20250130__20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_zLyZVs88Ekol" title="Fair value of shares issued">1,963,000 on the issuance date. The agreement has an initial term of three years, renewable for up to three additional one-year terms, subject to notice provisions. Propre Energie Inc. retains the right to terminate in the event the Company sells substantially all assets or a majority interest in the business. Either party may terminate in the event of breach (with a 90-day cure period) or insolvency. The agreement is accounted for as an intangible asset under ASC 350-30, given the exclusive licensing rights and identifiable future economic benefits. The asset is capitalized on a straight-line over <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_z6LdMbwY6AW1" title="Finite lived intangible assets, estimated useful lives">three years, subject to annual impairment review in accordance with US GAAP. <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zpmVnW0iCFY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of master distribution agreements as of March 31, 2026 is as follows: SCHEDULE OF CARRYING AMOUNT OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross carrying amount:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,963,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--FiniteLivedIntangibleAssetsAccumulatedCapitalization_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_znOMi6sXC0s" title="Accumulated capitalization:">(615,075</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,239,942</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,983</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Amortization (recorded as an operating expense) for the three months ended March 31, 2026 was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zCbsRPaP4hMg">14,523, reflecting the post-impairment carrying value amortized over the remaining initial term on a straight-line basis. During the year ended December 31, 2025, management determined that renewal beyond the initial 3-year term could not be guaranteed. Fair value of the distribution rights, estimated using a discounted cash flow analysis over the initial term, was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_903_ecustom--FairValueOfDistributionRights_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zsmajmFa3rJb">122,505, which was less than the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_ecustom--FairValueOfDistributionRightsCarryingValue_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zI2HUoG7op7k">1,362,447 carrying value. Accordingly, an impairment charge of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--OtherAssetImpairmentCharges_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zRe1PSNYwy4j">1,239,942 was recognized during the year ended December 31, 2025. The estimated amortization expense over the remaining term of the agreement is as follows: <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zZmZygOPcAp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF ESTIMATED AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Year 1:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zC3I4KYxeVwf" title="Year 1">44,375</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Year 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zU8TQguXkvB2" title="Year 2">58,899</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Year 3:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,983</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Foreign Currency Translation and transaction The Company’s principal country of operations is the United States. The financial position and results of its operations are determined using U.S. Dollars (“US$” or “$”), the local currency, as the functional currency. The Company’s condensed consolidated financial statements are reported using the U.S. Dollars. The results of operations and the statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital contribution. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets. Translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income (loss) included in statements of changes in shareholders’ equity. Gains and losses from foreign currency transactions are included in the Company’s statements of operations and comprehensive income (loss). MangoRx Mexico S.A. de C.V. operations are originally recorded in Mexican Pesos (MX$), prior to conversion to US$. <p id="xdx_891_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_zrKzjbsknGbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table outlines the currency exchange rates that were used in preparing the condensed consolidated financial statements: SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; width: 60%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: center; width: 16%">March 31,</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: center; width: 16%">December 31,</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end spot rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">US$1=MX$<span id="xdx_900_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20260331__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zK0taVV5bCJ" title="Currency exchange rate">0.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">US$1=MX$<span id="xdx_90C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20251231__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zSm6XyUKSa8e" title="Currency exchange rate">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Average rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">US$1=MX$<span id="xdx_900_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20260331__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zLboe6VfZr3e" title="Currency exchange rate">0.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">US$1=MX$<span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20251231__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zbkQYBm2apTb" title="Currency exchange rate">0.05</td><td style="text-align: left"> </td></tr> </table> Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zkwMrTesmdff" title="Anti-dilutive securities">2,156,666 options, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk0rNUTaMpB9" title="Anti-dilutive securities">2,928,401 warrants, and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zFqKE1B8Vvjd" title="Anti-dilutive securities">no derivative securities outstanding as of March 31, 2026. There were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zioYhrV9gWuc" title="Anti-dilutive securities">156,667 options, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zrrAqjYpVQHb" title="Anti-dilutive securities">1,742,333 warrants, and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zKUwTvNhBs05" title="Anti-dilutive securities">no derivative securities outstanding as of March 31, 2025. Use of Estimates and Assumptions The preparation of condensed consolidated financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates. Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with Financial Accounting Standards Board (FASB) ASC 820, Fair Value Measurement (“ASC 820”), which provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. <p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zVs3LDf6ziOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following tables summarize our financial instruments measured at fair value as of March 31, 2026 and December 31, 2025. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLf7j4yrWjEk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_znDW9GIraeS5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRjA0BxrQhrl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zEw7qpmMmwQ6" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">174,562</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zu0tGPZipO22" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> -</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zgXI9fvIapV5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_z003xKDHNfXc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value, net asset (liability)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">174,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAIc59MoiBD" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUl462aXqTRj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM7VVtwpL7A6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zaZg6Kw0779j" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,486,338</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zcqbCIt0DoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,338</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zbCwHi1S6FS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_zGSQM4NyO15b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Fair value, net asset (liability) </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,486,338</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Property, Plant and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three (3) to five (5) years. During the three months ended March 31, 2026 and 2025, the Company acquired computers and office equipment totaling $-0- and $-0-, respectively. Depreciation for the three months ended March 31, 2026 and 2025 was $250 and $250, respectively. SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_zkT5i7mtukoa" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zpMuhsVhWIb3" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zG5r4CJ3IGmh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Computers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zEFdR6FgUfMf" style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zwE7h77rtSc6" style="display: none; vertical-align: bottom; background-color: White"> <td>Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zYXC27vzM1fg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Less accumulated depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,518</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,268</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--DisposedPropertyPlantAndEquipment_iNI_di_zQtspMA2a3p2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Disposed equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iI_zS5McKRM8kJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,544</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,794</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the three months ended March 31, 2026 and 2025, the Company had no significant revenue from continuing operations, which were derived from a single or a few major customers. We rely on a limited number of major vendors/suppliers to fulfill clients’ prescriptions. We are currently limiting sales of our testosterone replacement therapy product sales to clients in the state of Florida, with plans to expand nationally as we grow. Black-Scholes Option Pricing Model The Company measures all options and warrants at fair value on the grant date. In accordance with ASC 718-20-35, the grant-date fair value of equity-classified awards is not remeasured after the grant date. If an award is modified, the Company recognizes incremental compensation cost, defined as the excess of the fair value of the modified award over the fair value of the original award immediately before the modification There were no warrants or options granted or issued during the period ended March 31, 2026. Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares. The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares. The Company accounts for its currently issued warrants in conjunction with the Company’s common stock shares in permanent equity. These warrants are indexed to the Company’s stock and meet the requirements of equity classification as prescribed under ASC 815-40. Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as the warrants continue to be classified as equity. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income (Subtopic 220-40). This ASU clarifies effective dates for expense disaggregation disclosures. It is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. This ASU has not yet been adopted by the Company. The Company does not expect the adoption to have a material impact on its condensed consolidated financial statements. In March 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810). This ASU provides guidance on determining the accounting acquirer in acquisitions involving variable interest entities (VIEs). It is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. This ASU has not yet been adopted by the Company. The Company does not expect the adoption to have a material impact on its condensed consolidated financial statements. In April 2025, the FASB issued ASU No. 2025-04, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606). This ASU clarifies accounting for share-based consideration payable to a customer. It is effective for fiscal years beginning after December 15, 2026. This ASU has not yet been adopted by the Company. The Company does not expect the adoption to have a material impact on its condensed consolidated financial statements. Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The condensed consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 4, 6, 7, and 8 in the notes to condensed consolidated financial statements. Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718, Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant. Revenue Recognition The Company follows the provisions of FASB ASC 606, Revenue from Contracts with Customers, for recording and recognizing revenue. The Company generates revenue through the sale of products and services purchased by customers directly through its online platform. Online revenue represents the sales of products on the Company’s platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP. Online revenue is generated by selling directly to consumers through the Company’s websites. The Company recognizes revenue when it transfers promised goods to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods and has satisfied its performance obligation. The Company defines its customer as an individual who purchases products through its websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products to the customer. All of the Company’s contracts with customers contain a single performance obligation: the delivery of products. For prescription product orders, customers undergo a medical evaluation conducted through the Company’s telemedicine platform prior to fulfillment. This evaluation is provided at no charge to the customer, including in instances where the customer does not qualify for a prescription and no product is delivered. As the medical evaluation has no standalone value to the customer independent of the product purchase, it does not represent a separate performance obligation under ASC 606, and the associated costs are recognized in cost of revenue. The Company satisfies its performance obligation at a point in time, which is upon delivery of the products to a third-party carrier. The customer obtains control of the products upon the Company’s completion of its performance obligation. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers conduct medical evaluations for its customers; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the products and services provided; (iii) the Company incurs costs for medical evaluations even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to fulfill its promise to customers for contracts that include the sale of prescription products. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills prescriptions based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. Variable Consideration. Refunds, credits, and chargebacks represent variable consideration under ASC 606. The Company estimates these amounts using the expected value method based on historical experience and current trends. Such amounts are recorded as a reduction of revenue in the period in which the related sales occur and are not expected to be subject to significant reversal. Remaining Performance Obligations. The Company applies the practical expedient under ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. All of the Company’s contracts with customers qualify for this practical expedient. Disaggregation of Revenue. The Company generates all revenue through a single channel: the direct sale of products to consumers through its online platform. Consultation services are provided as part of the prescription evaluation process at no charge to the customer and do not represent a separate revenue stream. Management believes this single category of online revenue appropriately depicts how economic factors affect the nature, amount, timing, and uncertainty of the Company’s revenue and cash flows, consistent with the disaggregation objective of ASC 606-10-50-5. Inventories Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the three months ended March 31, 2026 and 2025, there were no inventory write-downs. Subsequent Events The Company follows the guidance in Section 855-10-50 of FASB ASC 855, Subsequent Events, for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the condensed consolidated financial statements were issued (see Note 10). Digital Asset Treasury Activity The Company does not hold digital assets for investment or treasury purposes and had no crypto asset holdings or balances in transfer accounts as of March 31, 2026. The Company accounts for digital assets in accordance with ASC 350-60, Intangibles—Goodwill and Other—Crypto Assets. Under this guidance, digital assets are measured at fair value, with changes in fair value recognized in earnings. However, because all digital assets received during the period were promptly converted to fiat currency, no material gains or losses were recognized in connection with these transactions. The Company maintains internal controls over digital asset transfers, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Verification of counterparties and wallet addresses,</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Authorization protocols for initiating transfers, and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Daily reconciliation of crypto-to-fiat conversions.</td></tr> </table> The Company does not classify digital assets as cash or cash equivalents under ASC 305, and such assets are not included in liquidity metrics unless and until converted to fiat currency.

Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations, and cash flows for the interim periods presented have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. The results for the three months ended March 31, 2026, are not necessarily indicative of the results to be expected for the full fiscal year. The condensed consolidated financial statements present the financial position, results of operations and cash flows of the Company in accordance with US GAAP. All dollar amounts are rounded to the nearest thousand dollars.

Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation on the condensed consolidated statements of operations. Prior period salary and benefits in the amount of $276,815, were reclassified to interest expense - amortization of intangible assets on the statement of operations.

276815

Cash and Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $250,000 per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, the excess would be at risk of loss for purposes of the statement of cash flows. There are no cash equivalents at March 31, 2026 and December 31, 2025.

250000

December 2024 Subsidiary Reorganization On December 13, 2024, the Company, entered into a Parent Subsidiary Contribution Agreement with Mango & Peaches Corp., a Texas corporation (“Mango & Peaches”), a then recently formed wholly-owned subsidiary of the Company (the “Contribution Agreement”). Pursuant to the Contribution Agreement, the Company contributed substantially all of its assets, including ownership of: (a) its <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20241213__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxMexicoMember_zGn3mparRoDk" title="Equity ownership percentage">98% ownership of MangoRx Mexico S.A. de C.V., a Mexican Stock Company; and (b) its <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20241213__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember_zw3brPX1VHgk" title="Equity ownership percentage">100% ownership of MangoRx UK Limited, a company incorporated under the laws of the United Kingdom (collectively, the “Contributed Assets”), to Mango & Peaches, in order to restructure the ownership and operations of the Company, better segregate such operations and liabilities and provided for the issuance of a portion of the capital of Mango & Peaches to Mr. Jacob Cohen, the Chief Executive Officer of the Company (the “Subsidiary Reorganization”).

0.98

Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Mangoceuticals, Inc. and its consolidated subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

Non-Controlling Interest The Company consolidates MangoRx Mexico S.A. de C.V., in which it holds a 98% ownership interest. The remaining 2% ownership interest held by third parties is presented as non-controlling interest, a separate component of stockholders’ equity in the accompanying consolidated balance sheets. The operations of MangoRx Mexico S.A. de C.V. are minimal, and the non-controlling interest balance and net income (loss) attributable to non-controlling interest for the periods presented are not material to the condensed consolidated financial statements. The Company also consolidates Mango & Peaches Corp. (“M&P”), in which it holds a <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoAndPeachesCorpMember_zc5Y6IWPnxEa" title="Equity ownership percentage">51% ownership interest based on majority voting interest. Jacob Cohen, the Company’s Chief Executive Officer and Chairman, holds the remaining 49% of M&P’s common stock. Pursuant to a Clarification Agreement entered into between M&P and Mr. Cohen, effective as of May 13, 2025 (the date the shares of M&P were originally issued to Mr. Cohen), Mr. Cohen’s 49% common stock interest in M&P carries no obligation to absorb losses, liabilities, deficits, or other negative economic attributes of M&P. Due to M&P’s accumulated deficit and the absence of current positive equity value, no noncontrolling interest has been recognized with respect to Mr. Cohen’s interest in M&P, as any such balance is de minimis and immaterial to the condensed consolidated financial statements. This conclusion will be reassessed in future periods.

0.98

0.02

0.51

0.49

Segment Reporting The Company operates as a single operating segment. The Chief Decision-Making Officer (CDOM) reviews financial information on a consolidated basis for purposes of allocating resources and assessing performance. As such, the Company has determined that it operates in one reportable segment in accordance with Accounting Standards Codification (“ASC”) Topic 280, Segment Reporting. The Company’s operations are managed as a unified business, with consistent products and services offered across its customer base. The nature of the products and services, production processes, customer types, and distribution methods are substantially similar throughout the Company’s activities. All revenues, expenses, assets, and liabilities are evaluated collectively, and no discrete financial information is prepared or reviewed at a lower level. Accordingly, no additional segment information is presented

Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes. Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740. ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

Intangible Assets Patents The Company’s intangible assets consist of patents acquired through purchase, as described above. These patents are classified as finite-lived intangible assets and are amortized on a straight-line basis over their estimated useful lives, which range from <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_z2h4osEJ9xTi" title="Finite lived intangible assets, estimated useful lives years">14 to <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zdcWAQXyGV47" title="Finite-lived intangible assets, estimated useful lives">17 years. <p id="xdx_896_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znr55chgSuhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of patents as of March 31, 2026 is as follows: SCHEDULE OF CARRYING AMOUNT OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross carrying amount:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,954,150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated amortization:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zll2qw0Zwj21" title="Accumulated amortization">2,120,987</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,833,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuJ4nblNd1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Amortization expense for the three months ended March 31, 2026 was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zsH3SRdBiJX" title="Amortization expense">276,815. The estimated amortization expense for the next five years is as follows: SCHEDULE OF ESTIMATED AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Year 1:</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 16%"> <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2do6yf10lc7" title="Year 1">1,122,639</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year 2:</td> <td> </td> <td> </td> <td style="text-align: right"> <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zaPDVukHrLtl" title="Year 2">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year 3:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year 4:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year 5:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Thereafter:</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8bAKCjrCV5" title="Thereafter:">8,219,968</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total:</td> <td> </td> <td>$</td> <td style="text-align: right">13,833,163</td> <td> </td></tr> </table> The Company performs periodic impairment testing for its intangible assets to ensure that the carrying amount does not exceed the recoverable amount. For the three months ended March 31, 2026, no impairment losses were recognized. Master Distribution Agreements On January 30, 2025, the Company entered into a Master Distribution Agreement (“MDA”) with Propre Energie Inc., granting the Company a license to certain intellectual property and patent rights related to clinically proven plant-based formulations under the brand Dermytol®. These formulations target hyperpigmentation, dark spots, uneven skin tone, and skin brightening. As consideration, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20250130__20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_zbxVm72wgmqa" title="Common shares issued for consideration">650,000 common shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_z1aF8NBjkKl1" title="Common stock par value">0.0001 and a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20250130__20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_zLyZVs88Ekol" title="Fair value of shares issued">1,963,000 on the issuance date. The agreement has an initial term of three years, renewable for up to three additional one-year terms, subject to notice provisions. Propre Energie Inc. retains the right to terminate in the event the Company sells substantially all assets or a majority interest in the business. Either party may terminate in the event of breach (with a 90-day cure period) or insolvency. The agreement is accounted for as an intangible asset under ASC 350-30, given the exclusive licensing rights and identifiable future economic benefits. The asset is capitalized on a straight-line over <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20250130__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PropreEnergieIncMember_z6LdMbwY6AW1" title="Finite lived intangible assets, estimated useful lives">three years, subject to annual impairment review in accordance with US GAAP. <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zpmVnW0iCFY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of master distribution agreements as of March 31, 2026 is as follows: SCHEDULE OF CARRYING AMOUNT OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross carrying amount:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,963,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--FiniteLivedIntangibleAssetsAccumulatedCapitalization_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_znOMi6sXC0s" title="Accumulated capitalization:">(615,075</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,239,942</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,983</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Amortization (recorded as an operating expense) for the three months ended March 31, 2026 was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zCbsRPaP4hMg">14,523, reflecting the post-impairment carrying value amortized over the remaining initial term on a straight-line basis. During the year ended December 31, 2025, management determined that renewal beyond the initial 3-year term could not be guaranteed. Fair value of the distribution rights, estimated using a discounted cash flow analysis over the initial term, was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_903_ecustom--FairValueOfDistributionRights_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zsmajmFa3rJb">122,505, which was less than the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_ecustom--FairValueOfDistributionRightsCarryingValue_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zI2HUoG7op7k">1,362,447 carrying value. Accordingly, an impairment charge of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--OtherAssetImpairmentCharges_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zRe1PSNYwy4j">1,239,942 was recognized during the year ended December 31, 2025. The estimated amortization expense over the remaining term of the agreement is as follows: <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zZmZygOPcAp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF ESTIMATED AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Year 1:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zC3I4KYxeVwf" title="Year 1">44,375</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Year 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zU8TQguXkvB2" title="Year 2">58,899</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Year 3:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,983</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P14Y

P17Y

<p id="xdx_896_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znr55chgSuhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of patents as of March 31, 2026 is as follows: SCHEDULE OF CARRYING AMOUNT OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross carrying amount:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,954,150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated amortization:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zll2qw0Zwj21" title="Accumulated amortization">2,120,987</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,833,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

15954150

2120987

13833163

<p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuJ4nblNd1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Amortization expense for the three months ended March 31, 2026 was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgU0lHTklGSUNBTlQgQUNDT1VOVElORyBQT0xJQ0lFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zsH3SRdBiJX" title="Amortization expense">276,815. The estimated amortization expense for the next five years is as follows: SCHEDULE OF ESTIMATED AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Year 1:</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 16%"> <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2do6yf10lc7" title="Year 1">1,122,639</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year 2:</td> <td> </td> <td> </td> <td style="text-align: right"> <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zaPDVukHrLtl" title="Year 2">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year 3:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year 4:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year 5:</td> <td> </td> <td> </td> <td style="text-align: right">1,122,639</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Thereafter:</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8bAKCjrCV5" title="Thereafter:">8,219,968</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total:</td> <td> </td> <td>$</td> <td style="text-align: right">13,833,163</td> <td> </td></tr> </table>

276815

1122639

8219968

13833163

650000

0.0001

1963000

P3Y

<p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zpmVnW0iCFY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of master distribution agreements as of March 31, 2026 is as follows: SCHEDULE OF CARRYING AMOUNT OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross carrying amount:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,963,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--FiniteLivedIntangibleAssetsAccumulatedCapitalization_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_znOMi6sXC0s" title="Accumulated capitalization:">(615,075</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,239,942</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,983</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1963000

-615075 -1239942

107983

14523

122505 1362447

1239942

<p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zZmZygOPcAp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF ESTIMATED AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Year 1:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zC3I4KYxeVwf" title="Year 1">44,375</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Year 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--MasterDistributionAgreementMember_zU8TQguXkvB2" title="Year 2">58,899</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Year 3:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,983</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

44375

58899

4709

107983

Foreign Currency Translation and transaction The Company’s principal country of operations is the United States. The financial position and results of its operations are determined using U.S. Dollars (“US$” or “$”), the local currency, as the functional currency. The Company’s condensed consolidated financial statements are reported using the U.S. Dollars. The results of operations and the statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital contribution. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets. Translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income (loss) included in statements of changes in shareholders’ equity. Gains and losses from foreign currency transactions are included in the Company’s statements of operations and comprehensive income (loss). MangoRx Mexico S.A. de C.V. operations are originally recorded in Mexican Pesos (MX$), prior to conversion to US$. <p id="xdx_891_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_zrKzjbsknGbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table outlines the currency exchange rates that were used in preparing the condensed consolidated financial statements: SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; width: 60%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: center; width: 16%">March 31,</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: center; width: 16%">December 31,</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end spot rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">US$1=MX$<span id="xdx_900_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20260331__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zK0taVV5bCJ" title="Currency exchange rate">0.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">US$1=MX$<span id="xdx_90C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20251231__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zSm6XyUKSa8e" title="Currency exchange rate">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Average rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">US$1=MX$<span id="xdx_900_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20260331__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zLboe6VfZr3e" title="Currency exchange rate">0.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">US$1=MX$<span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20251231__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zbkQYBm2apTb" title="Currency exchange rate">0.05</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_891_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_zrKzjbsknGbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table outlines the currency exchange rates that were used in preparing the condensed consolidated financial statements: SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; width: 60%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: center; width: 16%">March 31,</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: center; width: 16%">December 31,</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end spot rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">US$1=MX$<span id="xdx_900_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20260331__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zK0taVV5bCJ" title="Currency exchange rate">0.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">US$1=MX$<span id="xdx_90C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20251231__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zSm6XyUKSa8e" title="Currency exchange rate">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Average rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">US$1=MX$<span id="xdx_900_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20260331__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zLboe6VfZr3e" title="Currency exchange rate">0.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">US$1=MX$<span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20251231__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zbkQYBm2apTb" title="Currency exchange rate">0.05</td><td style="text-align: left"> </td></tr> </table>

0.06

0.05

Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zkwMrTesmdff" title="Anti-dilutive securities">2,156,666 options, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk0rNUTaMpB9" title="Anti-dilutive securities">2,928,401 warrants, and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zFqKE1B8Vvjd" title="Anti-dilutive securities">no derivative securities outstanding as of March 31, 2026. There were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zioYhrV9gWuc" title="Anti-dilutive securities">156,667 options, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zrrAqjYpVQHb" title="Anti-dilutive securities">1,742,333 warrants, and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zKUwTvNhBs05" title="Anti-dilutive securities">no derivative securities outstanding as of March 31, 2025.

2156666

2928401

156667

1742333

Use of Estimates and Assumptions The preparation of condensed consolidated financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.

Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with Financial Accounting Standards Board (FASB) ASC 820, Fair Value Measurement (“ASC 820”), which provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. <p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zVs3LDf6ziOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following tables summarize our financial instruments measured at fair value as of March 31, 2026 and December 31, 2025. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLf7j4yrWjEk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_znDW9GIraeS5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRjA0BxrQhrl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zEw7qpmMmwQ6" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">174,562</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zu0tGPZipO22" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> -</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zgXI9fvIapV5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_z003xKDHNfXc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value, net asset (liability)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">174,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAIc59MoiBD" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUl462aXqTRj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM7VVtwpL7A6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zaZg6Kw0779j" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,486,338</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zcqbCIt0DoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,338</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zbCwHi1S6FS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_zGSQM4NyO15b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Fair value, net asset (liability) </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,486,338</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zVs3LDf6ziOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following tables summarize our financial instruments measured at fair value as of March 31, 2026 and December 31, 2025. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLf7j4yrWjEk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_znDW9GIraeS5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRjA0BxrQhrl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zEw7qpmMmwQ6" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">174,562</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zu0tGPZipO22" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> -</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zgXI9fvIapV5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_z003xKDHNfXc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value, net asset (liability)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">174,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAIc59MoiBD" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUl462aXqTRj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM7VVtwpL7A6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zaZg6Kw0779j" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,486,338</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zcqbCIt0DoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,338</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zbCwHi1S6FS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_zGSQM4NyO15b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Fair value, net asset (liability) </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,486,338</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

174562

1486338

Property, Plant and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three (3) to five (5) years. During the three months ended March 31, 2026 and 2025, the Company acquired computers and office equipment totaling $-0- and $-0-, respectively. Depreciation for the three months ended March 31, 2026 and 2025 was $250 and $250, respectively. SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_zkT5i7mtukoa" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zpMuhsVhWIb3" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zG5r4CJ3IGmh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Computers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zEFdR6FgUfMf" style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zwE7h77rtSc6" style="display: none; vertical-align: bottom; background-color: White"> <td>Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zYXC27vzM1fg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Less accumulated depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,518</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,268</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--DisposedPropertyPlantAndEquipment_iNI_di_zQtspMA2a3p2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Disposed equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iI_zS5McKRM8kJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,544</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,794</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P3Y

P5Y

250

SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_zkT5i7mtukoa" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zpMuhsVhWIb3" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zG5r4CJ3IGmh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Computers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zEFdR6FgUfMf" style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zwE7h77rtSc6" style="display: none; vertical-align: bottom; background-color: White"> <td>Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zYXC27vzM1fg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Less accumulated depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,518</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,268</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--DisposedPropertyPlantAndEquipment_iNI_di_zQtspMA2a3p2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Disposed equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iI_zS5McKRM8kJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,544</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,794</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5062

3518

3268

1544

1794

Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the three months ended March 31, 2026 and 2025, the Company had no significant revenue from continuing operations, which were derived from a single or a few major customers. We rely on a limited number of major vendors/suppliers to fulfill clients’ prescriptions. We are currently limiting sales of our testosterone replacement therapy product sales to clients in the state of Florida, with plans to expand nationally as we grow.

Black-Scholes Option Pricing Model The Company measures all options and warrants at fair value on the grant date. In accordance with ASC 718-20-35, the grant-date fair value of equity-classified awards is not remeasured after the grant date. If an award is modified, the Company recognizes incremental compensation cost, defined as the excess of the fair value of the modified award over the fair value of the original award immediately before the modification There were no warrants or options granted or issued during the period ended March 31, 2026.

Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares. The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares. The Company accounts for its currently issued warrants in conjunction with the Company’s common stock shares in permanent equity. These warrants are indexed to the Company’s stock and meet the requirements of equity classification as prescribed under ASC 815-40. Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as the warrants continue to be classified as equity.

Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income (Subtopic 220-40). This ASU clarifies effective dates for expense disaggregation disclosures. It is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. This ASU has not yet been adopted by the Company. The Company does not expect the adoption to have a material impact on its condensed consolidated financial statements. In March 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810). This ASU provides guidance on determining the accounting acquirer in acquisitions involving variable interest entities (VIEs). It is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. This ASU has not yet been adopted by the Company. The Company does not expect the adoption to have a material impact on its condensed consolidated financial statements. In April 2025, the FASB issued ASU No. 2025-04, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606). This ASU clarifies accounting for share-based consideration payable to a customer. It is effective for fiscal years beginning after December 15, 2026. This ASU has not yet been adopted by the Company. The Company does not expect the adoption to have a material impact on its condensed consolidated financial statements.

Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The condensed consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 4, 6, 7, and 8 in the notes to condensed consolidated financial statements.

Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718, Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant.

Revenue Recognition The Company follows the provisions of FASB ASC 606, Revenue from Contracts with Customers, for recording and recognizing revenue. The Company generates revenue through the sale of products and services purchased by customers directly through its online platform. Online revenue represents the sales of products on the Company’s platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP. Online revenue is generated by selling directly to consumers through the Company’s websites. The Company recognizes revenue when it transfers promised goods to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods and has satisfied its performance obligation. The Company defines its customer as an individual who purchases products through its websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products to the customer. All of the Company’s contracts with customers contain a single performance obligation: the delivery of products. For prescription product orders, customers undergo a medical evaluation conducted through the Company’s telemedicine platform prior to fulfillment. This evaluation is provided at no charge to the customer, including in instances where the customer does not qualify for a prescription and no product is delivered. As the medical evaluation has no standalone value to the customer independent of the product purchase, it does not represent a separate performance obligation under ASC 606, and the associated costs are recognized in cost of revenue. The Company satisfies its performance obligation at a point in time, which is upon delivery of the products to a third-party carrier. The customer obtains control of the products upon the Company’s completion of its performance obligation. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers conduct medical evaluations for its customers; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the products and services provided; (iii) the Company incurs costs for medical evaluations even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to fulfill its promise to customers for contracts that include the sale of prescription products. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills prescriptions based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. Variable Consideration. Refunds, credits, and chargebacks represent variable consideration under ASC 606. The Company estimates these amounts using the expected value method based on historical experience and current trends. Such amounts are recorded as a reduction of revenue in the period in which the related sales occur and are not expected to be subject to significant reversal. Remaining Performance Obligations. The Company applies the practical expedient under ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. All of the Company’s contracts with customers qualify for this practical expedient. Disaggregation of Revenue. The Company generates all revenue through a single channel: the direct sale of products to consumers through its online platform. Consultation services are provided as part of the prescription evaluation process at no charge to the customer and do not represent a separate revenue stream. Management believes this single category of online revenue appropriately depicts how economic factors affect the nature, amount, timing, and uncertainty of the Company’s revenue and cash flows, consistent with the disaggregation objective of ASC 606-10-50-5.

Inventories Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the three months ended March 31, 2026 and 2025, there were no inventory write-downs.

Subsequent Events The Company follows the guidance in Section 855-10-50 of FASB ASC 855, Subsequent Events, for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the condensed consolidated financial statements were issued (see Note 10).

Digital Asset Treasury Activity The Company does not hold digital assets for investment or treasury purposes and had no crypto asset holdings or balances in transfer accounts as of March 31, 2026. The Company accounts for digital assets in accordance with ASC 350-60, Intangibles—Goodwill and Other—Crypto Assets. Under this guidance, digital assets are measured at fair value, with changes in fair value recognized in earnings. However, because all digital assets received during the period were promptly converted to fiat currency, no material gains or losses were recognized in connection with these transactions. The Company maintains internal controls over digital asset transfers, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Verification of counterparties and wallet addresses,</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Authorization protocols for initiating transfers, and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Daily reconciliation of crypto-to-fiat conversions.</td></tr> </table> The Company does not classify digital assets as cash or cash equivalents under ASC 305, and such assets are not included in liquidity metrics unless and until converted to fiat currency. NOTE 3 – DEPOSITS The Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $16,942. The lease expired on November 30, 2025 and the security deposit remained receivable at December 31, 2025. The security deposit was returned during the three months ended March 31, 2026. The Company signed a five-year lease agreement for office space, effective November 1, 2025 through October 31, 2030, which included an initial security deposit of $14,557. As of March 31, 2026 and December 31, 2025, the balance was $14,557 for each period, respectively. The Company signed a short-term lease agreement for office space, effective September 1, 2025, which included an initial security deposit of $2,400. As of March 31, 2026 and December 31, 2025, the balance was $2,400 for each period, respectively.

16942

14557

2400

NOTE 4 – LOANS FROM RELATED PARTIES On October 18, 2024, the Company entered into a $150,000 promissory note (the “Cohen Note”) with Cohen Enterprises, Inc., which entity is owned by Jacob D. Cohen, the Chairman and Chief Executive Officer of the Company (“Cohen Enterprises”), to evidence, document and memorialize (a) $50,000 loaned to the Company from Cohen Enterprises on March 18, 2024, and (b) $100,000 loaned to the Company from Cohen Enterprises on April 1, 2024, which amounts previously accrued no interest and were due on demand. The Cohen Note in the principal amount of $150,000, accrues interest at the rate of 8% per annum (12% upon the occurrence of an event of default), with interest accruing monthly in arrears and payable at maturity or earlier acceleration. The Cohen Note was due upon the earlier of January 2, 2025, and upon acceleration by Cohen Enterprises pursuant to the terms thereof upon default, or automatically upon certain bankruptcy events occurring. The Cohen Note may be prepaid without penalty, is unsecured and contains customary representations and covenants of the Company. The note includes customary events of default, and allows Cohen Enterprises the right to accelerate the amount due under the note upon the occurrence of such event of default, subject to certain cure rights. On December 13, 2024, Mr. Cohen sold his note in the amount of $150,000 to a third-party entity. The terms of the note remain unchanged; however, the note is no longer considered a related party, see Note 5. On May 2, 2025, the Company borrowed $100,000 from The Tiger Cub Trust, which trust is controlled by the Company’s Chief Executive Officer and Chairman, Jacob D. Cohen (“Tiger Cub”), and entered into a Promissory Note with Tiger Cub to evidence such loan. The Promissory Note has a principal balance of $100,000. The Promissory Note is unsecured and bears interest at a rate of 18% per annum, compounded monthly, and matures on the earliest of (i) May 2, 2026, (ii) acceleration upon an event of default at the option of the holder, or (iii) five business days following the closing of a Qualified Financing. On December 19, 2025, the note was paid in full, including accrued interest of $18,000 resulting in a loss on debt extinguishment of $<span id="xdx_901_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260331__dei--LegalEntityAxis__custom--TheTigerCubTrustMember_zH6BALsYztOf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Loss on debt extinguishment">6,450. On, and effective on July 21, 2025, the Company entered into an Agreement to Amend Promissory Note (the “Agreement to Amend”), with Tiger Cub, which trust is controlled by the Company’s Chief Executive Officer and Chairman, Jacob D. Cohen, pursuant to which (a) Tiger Cub and the Company agreed to amend and restate the Promissory Note into an Amended and Restated Convertible Promissory Note (the “A&R Note”); and (b) the Company granted Tiger Cub warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250731__dei--LegalEntityAxis__custom--TheTigerCubTrustMember_zX8I4dhFK8z4" title="Warrants to purchase common stock">50,000 shares of common stock (the “Tiger Cub Warrants”). The Agreement to Amend included certain representations and warranties to Tiger Cub. The A&R Note amended and restated the Promissory Note to (a) provide Tiger Cub the option to convert the principal and accrued interest under the note into shares of common stock of the Company at a conversion price each to the greater of (x) (1) $1.50; (2) if the A&R Note was entered into prior to the close of market on the date entered into, the greater of (i) the consolidated closing bid price, and the (ii) closing price, of the common stock of the Company on the last trading day prior to the date the A&R Note was entered into, plus $0.125; and (3) if the A&R Note was entered into after the close of market on the date entered into, the greater of (i) the consolidated closing bid price, and the (ii) closing price, of the common stock of the Company on the date the A&R Note was entered into, plus $0.125, and (y) the lowest price per share of common stock which would not, under applicable rules of the Nasdaq Capital Market, require stockholder approval for such issuance of common stock in connection with a conversion, taking into account all securities issuable in connection therewith—which conversion price was $1.785; and (b) remove the Mandatory Prepayment requirement. The Tiger Cub Warrants have an exercise price of $1.815 per share, a term through July 21, 2028 and cash only exercise rights. On December 4, 2025, the Company borrowed $75,000 from The Tiger Cub Trust, which trust is controlled by the Company’s Chief Executive Officer and Chairman, Jacob D. Cohen (“Tiger Cub”), and entered into a Promissory Note with Tiger Cub to evidence such loan. The Promissory Note has a principal balance of $75,000. The Promissory Note is unsecured and bears interest at a rate of 18% per annum, compounded monthly, and matures on the earliest of (i) December 4, 2026, (ii) acceleration upon an event of default at the option of the holder, or (iii) five business days following the closing of a Qualified Financing. On December 19, 2025, the note was paid in full, including accrued interest due through maturity of $13,500.

150000

50000

100000

150000

0.08

150000

100000

0.18

matures on the earliest of (i) May 2, 2026, (ii) acceleration upon an event of default at the option of the holder, or (iii) five business days following the closing of a Qualified Financing.

18000

6450

50000

The Agreement to Amend included certain representations and warranties to Tiger Cub. The A&R Note amended and restated the Promissory Note to (a) provide Tiger Cub the option to convert the principal and accrued interest under the note into shares of common stock of the Company at a conversion price each to the greater of (x) (1) $1.50; (2) if the A&R Note was entered into prior to the close of market on the date entered into, the greater of (i) the consolidated closing bid price, and the (ii) closing price, of the common stock of the Company on the last trading day prior to the date the A&R Note was entered into, plus $0.125; and (3) if the A&R Note was entered into after the close of market on the date entered into, the greater of (i) the consolidated closing bid price, and the (ii) closing price, of the common stock of the Company on the date the A&R Note was entered into, plus $0.125, and (y) the lowest price per share of common stock which would not, under applicable rules of the Nasdaq Capital Market, require stockholder approval for such issuance of common stock in connection with a conversion, taking into account all securities issuable in connection therewith—which conversion price was $1.785; and (b) remove the Mandatory Prepayment requirement.

1.815

2028-07-21

75000

0.18

13500

NOTE 5 – NOTES PAYABLE On December 13, 2024, Cohen Enterprises, Inc., which is owned and controlled by Jacob Cohen, our Chief Executive Officer, entered into a Note Purchase Agreement with Mill End Capital Ltd. (“Mill End”), and sold a Promissory Note totaling $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20241213__dei--LegalEntityAxis__custom--CohenEnterprisesIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MillEndCapitalLtdMember_zySmka2kPP8g">150,000 (the Cohen Note) to Mill End. The Promissory Note bears interest of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241213__dei--LegalEntityAxis__custom--CohenEnterprisesIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MillEndCapitalLtdMember_z0lgV31MF3q1">12% (default rate) and is due on January 2, 2025. On January 15, 2025, the Company entered into a Debt Conversion Agreement (the “Debt Conversion Agreement”) with Mill End, pursuant to which acquired by Mill End from Cohen Enterprises on December 13, 2024, for $<span id="xdx_900_eus-gaap--NotesPayableCurrent_iI_c20241213__us-gaap--TypeOfArrangementAxis__custom--DebtConversionAgreementMember__dei--LegalEntityAxis__custom--MillEndCapitalLtdMember_z0UPegQvrk45" title="Note payable">150,000. Pursuant to the Debt Conversion Agreement, on January 15, 2025, the Company and Mill End agreed to convert the entire $<span id="xdx_906_eus-gaap--NotesPayableCurrent_iI_c20250115__us-gaap--TypeOfArrangementAxis__custom--DebtConversionAgreementMember__dei--LegalEntityAxis__custom--MillEndCapitalLtdMember_zL8NnVTDwQa" title="Note payable">150,000 owed by the Company to Mill End under the Promissory Note, into an aggregate of <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250115__20250115__us-gaap--TypeOfArrangementAxis__custom--DebtConversionAgreementMember__dei--LegalEntityAxis__custom--MillEndCapitalLtdMember_zPbKF2Fs4XK6" title="Shares issued upon debt conversion">100,000 shares of restricted common stock of the Company, based on an agreed conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250115__us-gaap--TypeOfArrangementAxis__custom--DebtConversionAgreementMember__dei--LegalEntityAxis__custom--MillEndCapitalLtdMember_ztUO45hzEiFl" title="Debt conversion price">1.50 per share. Pursuant to the Debt Conversion Agreement, which included customary representations and warranties of the parties, Mill End agreed that the shares of common stock issuable in connection therewith were in full and complete satisfaction of amounts owed under the Converted Note. On April 15, 2025, the Company borrowed $500,000 from Indigo Capital LP (the “Holder”), which loan was evidenced by a Promissory Note dated April 15, 2025 (the “Indigo Note”). The Indigo Note is unsecured and bears interest at 18% per annum, compounded monthly, with accrued interest payable in full on the maturity date, subject to acceleration and prepayment terms as described below. The Inidigo Note matures on the earlier of (i) April 15, 2026 (the “Stated Maturity Date”), (ii) the date on which the Holder provides written notice of acceleration following an event of default or other specified triggering event, and (iii) five (5) business days following the closing of a Qualified Funding (a “Mandatory Prepayment”). “Qualified Financing” means a fundraising by the Company, other than in connection with the sale of notes on substantially similar terms as this note, after the date of the Indigo Note, for the principal purpose of raising capital. On, and effective on May 27, 2025, the Company entered into an Agreement to Amend Promissory Note (the “Agreement to Amend”), with the Holder, pursuant to which (a) the Holder and the Company agreed to amend and restate the Promissory Note into an Amended and Restated Convertible Promissory Note (the “A&R Note”); and (b) the Company granted the Holder warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250527__us-gaap--TypeOfArrangementAxis__custom--AgreementToAmendMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5UhEKLcfMvb" title="Warrants to purchase of common stock">275,482 shares of common stock (the “Holder Warrants”). The Agreement to Amend included certain representations and warranties to the Holder. The A&R Note amended and restated the Promissory Note to (a) provide the Holder the option to convert the principal and accrued interest under the note into shares of common stock of the Company at a conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250527__us-gaap--DebtInstrumentAxis__custom--AmendedAndRestatedPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJIZK2ycypGg" title="Conversion price">1.50 per share, subject to a <span id="xdx_907_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20250527__20250527__us-gaap--DebtInstrumentAxis__custom--AmendedAndRestatedPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5HQCIKfOkK1" title="Ownership limitation percentage">4.999% beneficial ownership limitation; and (b) remove the Mandatory Prepayment requirement. The Holder Warrants have an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250527__us-gaap--DebtInstrumentAxis__custom--AmendedAndRestatedPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLR0nItgiLge" title="Warrant exercise price per share">1.815 per share, a term through May 27, 2028 and cash only exercise rights. The Holder Warrants include a <span id="xdx_90A_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20250527__20250527__us-gaap--DebtInstrumentAxis__custom--AmendedAndRestatedPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2YsDuWN0cMg" title="Ownership limitation percentage">4.999% beneficial ownership limitation. If the Holder Warrants are exercised in full, a maximum of <span id="xdx_90B_ecustom--SharesIssuableUponExerciseOfWarrants_iI_c20250527__us-gaap--DebtInstrumentAxis__custom--AmendedAndRestatedPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvfXxFqvgVJ8" title="Shares issuable upon exercise of warrants">275,482 shares of common stock of the Company would be issuable upon exercise thereof. On July 16, 2025, Indigo Capital LP converted the full $500,000 principal amount of their note, and accrued interest of $90,000, into an aggregate of <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250716__20250716__dei--LegalEntityAxis__custom--IndigoCapitalLPMember_zJeNl9MC5Wz3" title="Common stock issued upon debt conversion">393,333 shares of common stock of the Company at a conversion price of $1.50 per share, as set forth in the convertible promissory note.

150000

0.12

150000

100000

1.50

500000

0.18

The Inidigo Note matures on the earlier of (i) April 15, 2026

275482

1.50

0.04999

1.815

0.04999

275482

500000

90000

393333

1.50

NOTE 6 – CAPITAL STOCK Preferred Stock The Company is authorized to issue up to 10,000,000 shares of preferred stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20260331_z0SOaM7Oukq1">0.0001 par value. Series B Convertible Preferred Stock On March 28, 2024 and amended on June 27, 2024, the Company designated <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zUN7vbmrs8of" title="Preferred stock, shares authorized">6,000 shares of the Company’s Series B Convertible Preferred Stock, par value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zmJ9J5ONfs62" title="Preferred stock, par value">0.0001 per share (the “Series B Preferred Stock”). Each Series B Preferred Stock share has a stated value equal to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_906_ecustom--PreferredStockStatedValue_iI_pid_c20240328_zq7cZ1k2ZQs8" title="Preferred stock stated value">1,100, subject to increase under the terms of the designation (the “Stated Value”). as of March 31, 2026 and December 31, 2025, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhXBCyZzF0q7" title="Preferred stock, shares outstanding">50 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKxL8MhSVft6" title="Preferred stock, shares outstanding">50 shares of Series B Preferred Stock issued and outstanding, respectively. Effective on January 3rd and 6th, 2025, we agreed to definitive terms on Securities Purchase Agreements (the “January 2025 SPAs”), with certain institutional accredited investors (the “January 2025 Purchasers”), pursuant to which the Company sold the January 2025 Purchasers, and the January 2025 Purchasers purchased from the Company, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250103__20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQkWBWgWCszd" title="Number of shares sold">300 shares of Series B Preferred Stock for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250103__20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdlD5CQ04Yog" title="Value of shares sold">300,000, and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBMxtq7XSL1" title="Warrants to purchase common stock">396,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250103__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcAcjEQTZJa7" title="Warrant exercise price">2.61 per share; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrY95DgMy2ub" title="Number of shares sold">500 shares of Series B Preferred Stock for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zm3Q5DKxcNS5" title="Value of shares sold">500,000, and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbHThaLrAfSl" title="Warrants to purchase common stock">660,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvMYFaHsvCHe" title="Warrant exercise price">2.59 per share; and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsS8JoZm6Bt2" title="Number of shares sold">50 shares of Series B Preferred Stock for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2vBrAYCZhHf" title="Value of shares sold">50,000, and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2woArsjZiRi" title="Warrants to purchase common stock">66,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zg2v3XZ3zncc" title="Warrant exercise price">2.59 per share, respectively. Each of the January 2025 SPAs closed on the dates they were entered into, and the warrants were granted on the same dates. On January 15, 2025, the Company sold the Purchaser the final <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250115__20250115__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zW1cz2c9rvtg" title="Number of shares sold">250 shares of Series B Preferred Stock (the “Final Fourth Closing Shares”) for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250115__20250115__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZ8bGm4UqyT7" title="Sale of stock">250,000 in connection with a partial and final closing of the Fourth Closing. On February 12, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250212__20250212__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zHxxKO8Emw13" title="Conversion of share">216 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zIbdC0tVuxWi" title="Aggregrate stated value">237,600) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250212__20250212__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2Q2C6fHIhah" title="Conversion of units">105,600 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250212__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zk6m2HSrLyQd" title="Preferred stock, convertible, conversion price">2.25 per share. On March 25, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zXPZHYoM5aul" title="Conversion of share">146 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z8qu4b4iyZL2" title="Aggregrate stated value">385,000) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zEsifdIiR9Gj" title="Aggregrate stated value">256,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zGA5ACLaszI" title="Preferred stock, convertible, conversion price">1.50 per share. On March 25, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zvitvfquXXPd" title="Conversion of share">116 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zuwPRo58qtLe" title="Aggregrate stated value">160,600) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zdqTl353IUoj" title="Aggregrate stated value">107,067 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zMvSVFD9DHBl" title="Preferred stock, convertible, conversion price">1.50 per share. On March 25, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zL0upxx5o8V" title="Conversion of share">350 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zZlKkZ4tMF9e" title="Aggregrate stated value">127,602) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250325__20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zKuWHmbZLa81" title="Aggregrate stated value">85,067 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250325__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zHqjh9mAtpY" title="Preferred stock, convertible, conversion price">1.50 per share. On March 26, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250326__20250326__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zDi0bSAxmvMi" title="Conversion of share">218 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250326__20250326__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zXcovguLvQSk" title="Aggregrate stated value">239,800) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250326__20250326__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z4wKUmf6WyCh" title="Aggregrate stated value">159,866 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250326__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zeXcx1C9rKwc" title="Preferred stock, convertible, conversion price">1.50 per share. On March 28, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_ziWV1NpX4aF9" title="Conversion of share">74 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zSzJmdPnFGHi" title="Aggregrate stated value">63,800) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zOzi1Ncajju1" title="Aggregrate stated value">42,533 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zaZXDiAQVbtf" title="Preferred stock, convertible, conversion price">1.50 per share. On March 28, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zyvdNhpLhynl" title="Conversion of share">260 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zql6YnK3vib8" title="Aggregrate stated value">286,002) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_ze9RRzkh3Lfk" title="Aggregrate stated value">190,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockOneMember_zwyAdra8lFs" title="Preferred stock, convertible, conversion price">1.50 per share. On March 28, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zlnKWvoK9gof" title="Conversion of share">58 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zwqegHjzFVzi" title="Aggregrate stated value">81,402) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250328__20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zNtyVPNibHxi" title="Aggregrate stated value, shares">54,267 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockTwoMember_zWnhj45FAs18" title="Preferred stock, convertible, conversion price">1.50 per share. On March 17, 2025, with the approval of the shareholders of the Company at the special meeting of shareholders held on the same date, the Company submitted to the Secretary of the State of Texas, an amendment to the Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., to: <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--CommonStockConversionFeatures_c20250317__20250317__us-gaap--TypeOfArrangementAxis__custom--SeriesBConvertiblePreferredStockDesignationMember_zWh8Am2YIkRl" title="Conversion, description">(a) reduce the conversion price set forth therein to a fixed price of $1.50 per share (subject to customary adjustments for stock splits) (compared to having a fixed conversion price of $2.25 prior to the amendment); (b) reduce the floor price set forth therein from $2.25 to $1.50 per share (subject to customary adjustments for stock splits); (c) remove the dividend rights set forth therein (except for standard participatory rights for dividends declared on the Company’s common stock); and exclude the Company’s then wholly-owned subsidiary, Mango & Peaches, from the definition of Change of Control Transaction thereunder (as a result, the issuance of securities of Mango & Peaches to Mr. Jacob Cohen, the Company’s Chief Executive Officer and Chairman, will not be a Change of Control Transaction, trigger an event of default under the Series B Preferred Stock or be deemed an Equity Condition (as defined in the designation of the Series B Preferred Stock)(the “Designation Amendment”). On April 3, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250403__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfThRtDPrJog" title="Conversion of share">350 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250403__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7KeD2p35Ghi" title="Aggregrate stated value">385,000) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250403__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7CZ51tiieQf" title="Conversion of units">256,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250403__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUH6ENN4OHpl" title="Preferred stock, convertible, conversion price">1.50 per share. On April 11, 2025, the Company agreed to definitive terms on a Securities Purchase Agreement with an institutional accredited investor pursuant to which the Company sold the Purchaser, and the Purchaser purchased from the Company <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250411__20250411__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zM0uMCsSqOX7" title="Number of shares sold">100 shares of Series B Convertible Preferred Stock of the Company for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250411__20250411__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zgRnQEyLmxfc" title="Value of shares purchased">100,000. On April 28, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250428__20250428__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zISo2XaWzEwl" title="Conversion of share">100 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250428__20250428__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWHPHzakfgQk" title="Aggregrate stated value">110,000) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250428__20250428__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOy4tqVe1oPd" title="Conversion of units">73,333 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250428__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z34bEKI63Cig" title="Preferred stock, convertible, conversion price">1.50 per share. On May 1, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250501__20250501__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zepw1VWpLur6" title="Conversion of share">300 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250501__20250501__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zWrW0WDQoiid" title="Aggregrate stated value">330,000) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250501__20250501__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNzKaWwbK4wb" title="Conversion of units">220,000 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250501__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z17POOuekObj" title="Preferred stock, convertible, conversion price">1.50 per share. On June 5, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250605__20250605__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCzsh2fUXix" title="Conversion of share">100 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250605__20250605__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zoQ7rXbyMUC3" title="Aggregrate stated value">110,000) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250605__20250605__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgXHvEfk7tRa" title="Conversion of units">73,333 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250605__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaIAoaRejmdk" title="Preferred stock, convertible, conversion price">1.50 per share. On September 15, 2025, a holder of the Company’s Series B Convertible Preferred Stock converted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250915__20250915__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7NYeqwiXmwf" title="Conversion of share">500 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250915__20250915__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9vgHsL4z0Nd" title="Aggregrate stated value">550,000) into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250915__20250915__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgdzHA5tqUe3" title="Conversion of units">366,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250915__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7fH1R3R3bl3" title="Preferred stock, convertible, conversion price">1.50 per share. On October 16, 2025, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20251016__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zar9SQtmGFz9" title="Conversion of share">32 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20251016__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBjwo9bn1ce9" title="Aggregrate stated value">35,200) were converted by the holder into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20251016__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTSPHypujY92" title="Conversion of units">23,467 shares of common stock at a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20251016__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlX8MxbI2mGd" title="Preferred stock, convertible, conversion price">1.50 per share. 6% Series C Convertible Cumulative Preferred Stock On April 18, 2024, the Company designated <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240418__20240418__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zYaqYXWHM3m8" title="Shares issued">6,250,000 shares of a then new series of preferred stock, par value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240418__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zUZSXKOUKAs3" title="Preferred stock, par value">0.0001 per share, the Company’s “6% Series C Convertible Cumulative Preferred Stock” (the “Series C Preferred Stock”). As of March 31, 2026 and December 31, 2025, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zC605ZMsJSf1" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zOcSStiktZT" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zkm9Owd1E1T" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zhPj1meUHckf" title="Preferred stock, shares outstanding">980,000 shares of Series C Preferred Stock issued and outstanding. The Series C Preferred Stock has a stated value equal to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20240418__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zTFTvScjTPn6" title="Preferred stock stated value">20 per share, subject to increase under the terms of the designation (the “Stated Value”). As of March 31, 2026 and December 31, 2025, arrearages in cumulative preferred dividends were $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--Dividends_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zsQikZLZmaBa" title="Dividends">2,272,109 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--Dividends_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zZmdtC1S440c" title="Dividends">1,979,109, respectively. Per the terms of the Series C Preferred Stock designation, undeclared dividends increase the stated value of the instruments. On April 24, 2024, the Company entered into a Patent Purchase Agreement, with Intramont Technologies, Inc. (“Intramont” and the “Intramont Purchase Agreement”). Pursuant to the Intramont Purchase Agreement, the Company purchased certain patents and patent applications owned by Intramont, related to the prevention of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV), in consideration for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember_zXbPP3HfKt93" title="Consideration amount">20,000,000, which was payable to Intramont by (a) the issuance of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zxBptnnRaw99" title="Number of shares issued for purchase of patent">980,000 shares of Series C Preferred Stock, with a face value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zweJv4jvQprk" title="Share price">20.00 per share, for a total value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zxUBBGVtp1t1" title="Value of shares issued for purchase of patent">19,600,000; and (b) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember_zJB8RiIeCYZ9" title="Cash payment">400,000 in cash, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_ecustom--CumulativePreferredStockDescription_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember_zyNgfAfdmITb" title="Cumulative preferred stock description">(i) with $200,000 payable on or before June 30, 2024, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024. The Company and Intramont had agreed to payment in full by December 31, 2024, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember_z7bqiCqyRbm7" title="Sale of stock value">27,000 was paid as of December 31, 2024. On February 11, 2025, and effective on December 31, 2024, we and Intramont entered into a letter agreement, amending the IP Purchase Agreement (the “Amendment Letter”), pursuant to which Intramont has agreed that all funds paid by the Company towards the furtherance and development of the Patents would be credited against the Cash Payments owed to Intramont and we agreed to work in good faith with Intramont on financing, developing and commercializing the Patents. As a result of the Amendment Letter, a total of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBQUkVGRVJSRUQgU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--Cash_iI_c20260331__us-gaap--AwardTypeAxis__custom--AmendmentLetterMember_zjiq8b6dcPnc" title="Cash payment">147,451 remains due to Intramont in connection with the Cash Payments as of March 31, 2026, which the Company expects to pay over time, by way of expenses associated with the development of the Patents. Common Stock The Company is authorized to issue <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zSRH1lLDqzT6" title="Common stock, shares authorized">200,000,000 shares of common stock, par value $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zc16Vbni2Nv7" title="Common stock, par value">0.0001 per share, of which <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20260331_zPNLUJsSLmk8" title="Common stock, shares outstanding">16,967,421 shares were issued and outstanding at March 31, 2026, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zJY39wzKaipg" title="Common stock, shares outstanding">15,888,795 shares were issued and outstanding at December 31, 2025. On January 1, 2026, we entered into a Third Amendment to Consulting Agreement with LSTM whereby LSTM agreed to provide additional general consulting services as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the additional services under the agreement, the Company issued LSTM an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260101__20260101__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LSTMHoldingsLLCMember_zLhRAIARtQB6" title="Number of shares issued for services">400,000 shares (for a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20261231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementLSTMMember_zagkO0l4nfJ1" title="Stock issued during period, shares, new issues">1,100,000 shares of common stock) which were issued under the Company’s 2022 Plan. The shares were valued at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20260101__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LSTMHoldingsLLCMember_zvgCAvjjtJIc" title="Shares price per share">0.74 per share for a total of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260101__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LSTMHoldingsLLCMember_zqhIgSmddNh9" title="Value of shares issued for services">296,000, which is included in stock-based compensation on the statement of operations. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--RestrictedCashAndCashEquivalentItemDescription_c20260101__20260101__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementLSTMMember_zSgzuT16Vj8l" title="Restricted cash and cash equivalent, nature of restriction, description">On January 12, 2026, we entered into another service agreement with Greentree. The Company and Greentree were previously party to a service agreement which expired pursuant to its terms on September 30, 2025. The Company agreed to issue Greentree <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20260112__20260112__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementLSTMMember_zmkCPF95gDJ3" title="Restricted stock, shares issued net of shares for tax withholdings">40,000 shares of the Company’s restricted common stock upon the parties’ entry into the agreement (fully-earned upon issuance), and to pay Greentree $40,000 in cash, payable as follows: (a) $20,000 on or before January 15, 2026; and (b) $20,000 on or before March 31, 2026, which is still due and outstanding as of the date of this report. We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree’s activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90D_eus-gaap--SharesIssued_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementLSTMMember_zqQlgF8Cebq1" title="Shares, issued">40,000 shares were issued to Greentree at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20260122__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LSTMHoldingsLLCMember_zoR03GDrhizl" title="Shares price per share">0.785 per share for a total of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260122__20260122_zc0zvXhtRA9c" title="Stock issued during period, value, new issues">31,400, which is included in stock-based compensation on the statement of operations. On January 22, 2026, we entered into a Consulting Agreement with Muhammad Azfar (“Azfar”) whereby Azfar agreed to provide general consulting services as reasonably requested by the Company during the term of the agreement, which was for 6 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the consulting services under the agreement, the Company issued Azfar <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--SharesIssued_iI_c20260122__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_zpZgiEdixeri" title="Shares, issued">75,000 shares which were issued under the Company’s 2022 Plan. The shares were valued at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20260101__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_zgvHSu2h6e8d" title="Shares issued, price per share">0.537 per share for a total of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260122__20260122__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_zF7CtUX2fDRj" title="Stock issued during period, value, new issues">40,275, which is included in stock-based compensation on the statement of operations. On March 13, 2026, the Company issued at total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--SharesIssued_iI_c20260313__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_zKdoWQl6EkS2" title="Shares, issued">313,625 shares of the Company’s common stock to and among eight (8) employees and contractors as a bonus and for services rendered for its then subsidiary, Mango & Peaches Corp. The shares were not subject to any vesting requirements and were issued under the Company’s 2022 Plan. The shares were issued at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90C_eus-gaap--SharePrice_iI_c20260313__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_zxOJTiNcE4jc" title="Share price">0.384 per share for a total of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260313__20260313__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_zc4q57LxoO56" title="Stock issued during the period, value">120,463, which is included in stock-based compensation on the statement of operations. On March 16, 2026, we entered into a Consulting Agreement with Gatorland Holdings, LLC (“Gatorland”) whereby Gatorland agreed to provide general business advisory and consulting services specifically related to its subsidiary, Mango & Peaches Corp and as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the consulting services under the agreement, the Company issued Gatorland <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--SharesIssued_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GatorlandHoldingsLlcMember_zCeOsHMdvat4" title="Shares, issued">250,000 shares which were issued under the Company’s 2022 Plan. The shares were issued at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--SharePrice_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_zUZr6Du29Wha" title="Share price">0.404 per share for a total of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBDT01NT04gU1RPQ0sgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMuhammadAzfarMember_z66ZDV63E32l" title="Stock issued during the period, value">101,000, which is included in stock-based compensation on the statement of operations. Options: The Company measures all equity-classified share-based payment awards at fair value on the grant date. In accordance with ASC 718-20-35, the grant-date fair value of equity-classified awards is not remeasured after the grant date. Compensation cost for these awards is recognized on a straight-line basis over the requisite service period, adjusted for actual forfeitures. Liability-classified awards are remeasured at fair value at each reporting date until settlement, with changes in fair value recognized in earnings for the period. If an award is modified, the Company recognizes incremental compensation cost, defined as the excess of the fair value of the modified award over the fair value of the original award immediately before the modification. During the year ended December 31, 2022, the Company granted a total of options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_zEjHnt4kbCAe" title="Number of options granted">83,333 shares of common stock of the Company, under the 2022 Plan, of which <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zaFkvPhIrdO3" title="Number of options granted">50,000 were granted to Jacob Cohen, the Company’s CEO, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zZ9BC2CYMG7d" title="Number of options granted">33,333 were granted to Jonathan Arango, the Company’s then President and then COO, related to their respective employment agreement. The options have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_zviErWyyVhy6" title="Exercise price">16.50 per share, an original life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_zCLYEPZdGXn2" title="Options life">five years and vest at the annual renewal of their employment over three years. On May 1, 2023, the Company granted options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230501__20230501__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zsADdBhE7P3g" title="Number of options granted">10,000 shares of common stock of the Company, under the 2022 Plan to Amanda Hammer, the Company’s then COO, related to her employment agreement. The options have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230501__20230501__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zfY1VWOgF6fl" title="Exercise price">16.50 per share, an original life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230501__20230501__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zgHMrU0hZ00k" title="Options life">five years and vest at the annual renewal of their employment over three years. On December 28, 2023, the Company granted options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231228__20231228__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z6PO65XTCVNi" title="Number of options granted">83,333 shares of common stock of the Company, under the 2022 Plan to Jacob Cohen, the Company’s CEO, related to his employment agreement. The options have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231228__20231228__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcUndPRb9h1f" title="Exercise price">4.80 per share, an original life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20231228__20231228__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zw5gjD6WLSNi" title="Options life">five years and vested at the time of grant. On March 28, 2024, Mr. Arango resigned from his position as President and Director of the Company. As detailed in his employment agreement, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240328__20240328__srt--TitleOfIndividualAxis__custom--JohnathanArangoMember_zUtpwyYFTH57" title="Number of unvested options forfeited">18,889 unvested options were forfeited upon resignation or termination of employment as an officer and director. Mr. Arango did not exercise his <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240628__20240628__srt--TitleOfIndividualAxis__custom--JohnathanArangoMember_zfS1oWqtYgB3" title="Number of options not exercised">14,444 vested options by the June 28, 2024 deadline for exercise, resulting in all vested options being terminated. On July 12, 2024, the Company granted options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240712__20240712__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--RaffiSahulMember_zWzcUWuf9Fqa" title="Number of options granted">13,333 shares of common stock of the Company, under the 2022 Plan to Raffi Sahul, related to his agreement to serve as manager of MangoRx IP. The options have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240712__20240712__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--RaffiSahulMember_z1JR3ELVG7ge" title="Exercise price">5.55 per share, an original life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240712__20240712__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--RaffiSahulMember_z0GhvtrAVYu" title="Options life">three years and vested immediately. On September 9, 2025, the Company granted options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250909__20250909__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_znmSalgue67" title="Number of options granted">2,000,000 shares of common stock of the Company, under the 2022 Plan to Jacob Cohen, in consideration for services rendered and to be rendered to the Company as Chief Executive Officer of the Company. The options have a term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20250909__20250909__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zd8vfqYHZOdd" title="Options vesting period">ten years, an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250909__20250909__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdx3dhgyvEQc" title="Exercise price">2.30 per share, which was the closing sales price of the Company’s common stock on September 9, 2025, the grant date; vest over 18 months with <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20250909__20250909__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zYqJGDMwHiB1" title="Option vesting">500,000 of the options vesting upon grant and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250909__20250909__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zgc5OhVRuYpb" title="Option grant">500,000 of the options vesting on the 6th, 12th, and 18th month anniversaries of the grant date, subject to Mr. Cohen’s continued service with the Company on such vesting date; and vest in full upon any termination of Mr. Cohen by the Company without cause, or by Mr. Cohen for good reason, or upon a change of control of the Company. On March 16, 2026, upon the recommendation of the compensation committee of the Board of Directors of the Company, and pursuant to the authority provided to the Board pursuant to the terms of the Company’s 2022 Equity Incentive Plan, as amended and restated, which was previously been approved by the stockholders of the Company, the Board approved an option repricing (the “Repricing”) of the outstanding stock options held by the Company’s Chief Executive Officer and Chairman, Jacob Cohen, as of March 16, 2026. As permitted under the terms of the Company’s equity plans, the exercise price of each outstanding stock option with an exercise price held by Mr. Cohen was reduced to an amount which exceeded the closing price of the Company’s common stock on the Effective Date, which was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--StockOptionExercisePriceIncrease_c20260316__20260316_zCDCaw13k6A1" title="Stock exercise price">0.45 per share (the “New Exercise Price”). In total the following options held by Mr. Cohen were re-priced to have an exercise price equal to the New Exercise Price: (a) options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--MrJacobCohenMember_zg0QlXxAsK6j" title="Stock options exercisable price">50,000 shares of the Company’s common stock with an original exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--StockOptionExercisePriceIncrease_pid_c20220831__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--MrJacobCohenMember_zPFA10NjMlFa" title="Stock exercise price">16.50 per share, granted to Mr. Jacob Cohen on August 31, 2022; (b) options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--MrCohenMember_zUAUOEAwwfAk" title="Stock options exercisable price">83,333 shares of the Company’s common stock with an original exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--StockOptionExercisePriceIncrease_pid_c20231228__20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--MrCohenMember_z4VTVeBLLLz2" title="Stock exercise price">4.80 per share, granted to Mr. Cohen on December 28, 2023; and (c) options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250909__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--MrCohenMember_z3EjTTEcdQIb" title="Stock options exercisable price">2,000,000 shares of the Company’s common stock with an original exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--StockOptionExercisePriceIncrease_pid_c20250909__20250909__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--MrCohenMember_zbaaYDQztkZk" title="Stock exercise price">2.30 per share, granted to Mr. Cohen on September 9, 2025. In accordance with ASC 718-20-35, we have recorded an additional $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pid_c20260101__20260331_zYfgPVKjk0l5" title="Stock-based compensation">37,978 in stock-based compensation related to the price modification. Mr. Cohen is a related party. For the three months ended March 31, 2026 and 2025, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zoatgNoKLiGk" title="Stock-based compensation expense">1,090,114 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBPUFRJT05TIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmNoeSqfyzub" title="Stock-based compensation expense">50,979, respectively, have been recorded and included as stock-based compensation expense on the condensed consolidated statement of operations. The following table summarizes common stock option activity: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20250101__20251231_zAMfinXaFIS3" style="width: 16%; text-align: right" title="Options, Exercisable Beginning Balance">156,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20250101__20251231_zpszhe2slvgg" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">9.34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zw7ci0MbRtQb" style="text-align: right" title="Options, Granted">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231_zv1ZRPIgCqj7" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20251231_zJDmGoiVtbW2" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231_z5XHy5iQm2t3" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Expired / Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250101__20251231_zaDrkTBp1onk" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231_zHk5WgKikMtk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20260101__20260331_z4LdQIRs4fLf" style="text-align: right" title="Options, Exercisable Beginning Balance">2,156,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20260101__20260331_zmDNGMybRSIc" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331_zQb5fUa8oILg" style="text-align: right" title="Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331_z0T6eogPMdy5" style="text-align: right" title="Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260331_z789bRkAHvAh" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331_zfb8SU7k0kTb" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired / Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260331_z4LTbnhZfA07" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331_zwR6caSr5TDb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331_z4JLFkxtdDKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding Ending Balance">2,156,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331_zQTxc7Ti9ET9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331_zAFZg9G5kzla" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable Ending Balance">1,156,110</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331_zmMDD6FDtSAd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.65</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zZnNQYNcfkh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The weighted average exercise prices, remaining lives for options granted, and exercisable as of March 31, 2026 were as follows: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options Exercise Price Per Share</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Life (Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zKsAdY4nFych" style="width: 13%; text-align: right" title="Weighted Average Outstanding">16.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeG8OHMLJbZ1" style="width: 13%; text-align: right" title="Outstanding Options">10,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zyox2IiV3MV9" title="Options Term">.47</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXyJYDOt3sob" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price">16.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zQEMGzZ9i6N8" style="width: 13%; text-align: right" title="Exercisable Options">9,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zb4MG9zgftzd" style="width: 13%; text-align: right" title="Weighted Average Exercise Price, Exercisable">16.50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zA98vy3q5Hqd" style="text-align: right" title="Weighted Average Outstanding">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zYAlpAiMdTb3" style="text-align: right" title="Outstanding Options">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ztslH4BDIA0c" title="Options Term">.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSIkU7KQhMt7" style="text-align: right" title="Weighted Average Exercisable Price">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSfWASOPNDV9" style="text-align: right" title="Exercisable Options">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKBKYLG41h6j" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zvdWRJv5iFs8" style="text-align: right" title="Outstanding Options, Exercise Price Per Share">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zR9l7xwzBk77" style="text-align: right" title="Outstanding Options, shares">83,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zLuaKl8UIy6" title="Outstanding Options, Life (Years)">.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zaxwhxKiELE4" style="text-align: right" title="Exercisable Options, Weighted Average Exercise Price">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z78oJmz1VSm5" style="text-align: right" title="Exercisable Options, Shares">83,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zslqRaztKpPe" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z1K36JtjEPqh" style="text-align: right" title="Outstanding Options, Exercise Price Per Share">5.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zw3hWioQ2WA7" style="text-align: right" title="Outstanding Options, shares">13,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zeuYaQqEFpKi" title="Outstanding Options, Life (Years)">.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zSCjTgvY3827" style="text-align: right" title="Exercisable Options, Weighted Average Exercise Price">5.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zW7F3sRDkwH5" style="text-align: right" title="Exercisable Options, Shares">13,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zFWxncDlHRVj" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">5.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zRD38nlxX406" style="text-align: right" title="Outstanding Options, Exercise Price Per Share">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zqJW8Qs3iIR2" style="text-align: right" title="Outstanding Options, shares">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYnHGtFdHFMl" title="Outstanding Options, Life (Years)">9.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2y6H8XvJ8Q3" style="text-align: right" title="Exercisable Options, Weighted Average Exercise Price">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zQ84sw5ooCKg" style="text-align: right" title="Exercisable Options, Shares">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2zrK5iMfnJc" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.45</td><td style="text-align: left"> </td></tr> </table> As of March 31, 2026, the aggregate initial fair value of the options measured on the grant dates of August 31, 2022, May 1, 2023, December 28, 2023, July 12, 2024, and September 9, 2025 was calculated using the Black-Scholes option pricing model based on the following assumption: <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z866qrlMK8A6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of common stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__srt--RangeAxis__srt--MaximumMember_z45bchdLAcy9" title="Fair value of common stock on measurement date">30.47 – <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__srt--RangeAxis__srt--MinimumMember_zJx7ODxMFAma" title="Fair value of common stock on measurement date">0.37</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zSo4bjAtHsY2" title="Risk free interest rate">4.13% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zW8B6zDHSnje" title="Risk free interest rate">4.10</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zZID7z0gSKo" title="Volatility">145.38% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zyTXhgFoZ4E9" title="Volatility">125.78</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zzRn7qjgnyic" title="Expected Term">5.75 - <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zFKhX3NqMZP4" title="Expected Term">3.0</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The trading volatility was determined by calculating the volatility of the Company’s peer group.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company does not expect to pay a dividend in the foreseeable future.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company, in accordance with staff accounting bulletin (“SAB”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term.</td></tr> </table> Warrants: In August 2022, the Company initiated a private placement of up to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn6n6_c20220831__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zMpbkR4lLmvj" title="Warrants to purchase">2 million of units to accredited investors, with each unit consisting of one-fifteenth of a share of common stock and a warrant to purchase one-fifteenth of one share of common stock, at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220831__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zdp7Yxe49sla" title="Shares price per share">1.00 per unit (the “Private Placement Warrants”). The warrants have a five-year term (from each closing date that units were sold) and an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220831__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zrTA6518bkv4" title="Warrants exercise price per share">15.00 per share. In total, we sold an aggregate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220816__20221222__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__srt--TitleOfIndividualAxis__custom--TwentyThreeAccreditedInvestorsMember_zuwNWLCgvjq2" title="Number of shares issued">2,000,000 units for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220816__20221222__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__srt--TitleOfIndividualAxis__custom--TwentyThreeAccreditedInvestorsMember_zZvoctIcUrUf" title="Number of shares issued value">2,000,000 to 23 accredited investors between August 16, 2022 and December 22, 2022. There were Private Placement Warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zfGUmJsmOBt8" title="Exercise of warrants shares">65,033 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zAcyaWYUyAlg" title="Exercise of warrants shares">65,033 shares of common stock outstanding as of March 31, 2026 and December 31, 2025, respectively. As additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zYKmFBkEWmni" title="Warrants issued">5,833 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z1RzsDEj8o3j" title="Exercise price">75.00 per share, which were exercisable six months after the effective date of the registration statement filed in connection with the IPO (March 20, 2023) and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgD80ZEITKea" title="Warrants term">five years after such effectiveness date, or March 20, 2028. The fair value of the warrants on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20230319__20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_znMOf8eNMQr" title="Fair value of warrants">31,995. As additional consideration in connection with the follow-on offering, upon the closing of the follow-on offering, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the follow on offering following the IPO, warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zOxm4SyN23Z9" title="Warrants issued">18,667 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvCCMgIwk4hi" title="Exercise price">5.70 per share, which were exercisable six months after the effective date of the registration statement filed in connection with the follow-on offering (December 19, 2023) and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRNvIBXqWTSf" title="Warrants term">five years after such effectiveness date. The fair value of the warrants on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zN17JowzDCD1" title="Fair value of warrants">78,174. On January 22, 2024, pursuant to an Underwriting Agreement, the Company also issued a common stock purchase warrant to the representative of the underwriters for the purchase of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ8wmn9Rdnfl" title="Number of warrants to purchase of common stock">2,800 shares of its common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoxIIesIX29f" title="Exercise price per share">5.63, subject to adjustments. The warrants are exercisable at any time and from time to time, in whole or in part, until December 14, 2028, and may be exercised on a cashless basis. The warrants also include customary anti-dilution provisions and immediate piggyback registration rights with respect to the registration of the shares underlying the warrants. The warrants and the shares of common stock underlying the warrants were registered as a part of the follow-on registration statement. The fair value of the warrants on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240122__20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zsolnkbmANfk" title="Fair value of warrants">12,086. On April 4, 2024, pursuant to the SPA with the Purchaser, the Company issued a common stock purchase warrant for the purchase of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCzSjb3rsea8" title="Warrants to purchase common stock">220,000 shares of its common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6XOQu4fJXx3" title="Exercise price per share">3.90 per share to the Purchaser. The warrant is exercisable at any time and from time to time, in whole or in part, until April 4, 2029. The fair value of the warrant on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlCSdnMwSB05" title="Fair value of warrants">681,352. On June 28, 2024, pursuant to the SPA (as amended), the Company issued a common stock purchase warrant for the purchase of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEoUvkGBvgDj" title="Number of shares issued upon exercise">66,667 shares of its common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z135YWohAeg" title="Exercise price per share">7.50 per share to the Purchaser. The warrant is exercisable at any time and from time to time, in whole or in part, until June 28, 2029. The fair value of the warrant on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4HHgF6MRZLc" title="Fair value of warrants">260,750. On June 28, 2024, pursuant to the SPA (as amended), the Company issued a common stock purchase warrant for the purchase of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zAxcr5yxWGyi" title="Number of shares issued upon exercise">33,333 shares of its common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zqC3Bi0ivdsd" title="Exercise price per share">15.00 per share to the Purchaser. The warrant is exercisable at any time and from time to time, in whole or in part, until June 28, 2029. The fair value of the warrant on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zlYn39KUcxG9" title="Fair value of warrants">122,341. On August 22, 2024, we entered into a Consulting Agreement with Levo Healthcare Consulting, Inc. (“Levo”), to provide marketing services to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--OtherLiabilities_iI_pid_c20240822__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LevoHealthcareConsultingIncMember_zK8m8OHYuCs7" title="Cash payable for services">6,250 in cash and issue Levo <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240822__20240822__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LevoHealthcareConsultingIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zahoohJ0tdNl" title="Number of shares issued for services">13,000 shares of restricted common stock under the 2022 Plan. The shares were valued at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240822__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LevoHealthcareConsultingIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqbuqjyUtSoa">4.35 per share for a total of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240822__20240822__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LevoHealthcareConsultingIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3i0yVi2j6V" title="Stock issued during period, value, issued for services">56,160. The Company also agreed to issue warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240822__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LevoHealthcareConsultingIncMember_zqTEYtaiRqSh" title="Issuance of warrants">20,000 shares of common stock of the Company, based on certain milestones being met. The warrants will expire three years from the date of milestone being reached. The agreement contains customary confidentiality and non-solicitation provisions. None of the milestones had been met as of March 31, 2026. In accordance with ASC 718, we have calculated the fair value to be $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantFairValue_iI_c20240822__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LevoHealthcareConsultingIncMember_z30EU8w3NNv7" title="Fair value of shares">68,170 on the grant date of August 22, 2024, using the Black-Scholes Valuation Model. As of the date of this Report, no milestones have been met and therefore no warrants have been issued to Levo pursuant to the agreement. From December 18 - 31, 2024, pursuant to the December 2024 SPAs, the Company issued a common stock purchase warrant for the purchase of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20241218__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockPurchaseWarrantMember_zeyQLdL3QUIb" title="Number of shares issued upon exercise">528,000 shares of its common stock at a weighted average exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockPurchaseWarrantMember_zuES1Fnc4cMe" title="Exercise price per share">2.62 per share to the December 2024 Purchasers. The warrant is exercisable at any time and from time to time, in whole or in part, until December 18 -31, 2029. The fair value of the warrants on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20241218__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockPurchaseWarrantMember_zyHIsH7uTova" title="Fair value of warrants">1,193,887. Effective on January 3rd and 6th, 2025, we agreed to definitive terms on the January 2025 SPAs with the January 2025 Purchasers pursuant to which the Company sold the January 2025 Purchasers, and the January 2025 Purchasers purchased from the Company, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250103__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zR0c7stSSf5k">300 shares of Series B Preferred Stock for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250103__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zoI3WBqn9h7b">300,000, and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlulybp2q1h8">396,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZcs7Tgpr7Jf">2.61 per share; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250106__20250106__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1hpubebIiS1">500 shares of Series B Preferred Stock for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250106__20250106__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmlhsoJNxqJ">500,000, and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeHXOctRsRa8">660,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4uPgJd9Hvk7">2.59 per share; and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250106__20250106__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zk87NVV5maG" title="Number of shares issued, shares">50 shares of Series B Preferred Stock for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250106__20250106__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvLgZg0K9gle" title="Number of shares issued, value">50,000, and warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUuP9lDo2l3" title="Warrants to purchase">66,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFo72kBirvSg" title="Warrant exercise price">2.59 per share, respectively. Each of the SPAs closed on the dates they were entered into, and the warrants were granted on the same dates. The fair value of the warrants on the grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20250106__20250106_zAaFqZDHyU8k" title="Fair value of warrants">2,226,602. On February 10, 2025, the Company received a Notice of Exercise from a holder of warrants to purchase shares of common stock relating to the exercise of warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXY5mduBj9Ub" title="Warrant purchase">140,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zovgjaAnF6C4" title="Warrant exercise price">1.50 per share. The Company received the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250211__20250211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgMvgh5oGkC6" title="Aggregate exercise price">210,000 aggregate exercise price and issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250211__20250211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTodtMYwJuPj" title="Shares issued">140,000 shares of common stock to the prior holder on February 11, 2025. On February 11, 2025, the Company received a Notice of Exercise from a holder of warrants to purchase shares of common stock relating to the exercise of warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250211__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_z4OM2sijLEq3" title="Warrant purchase">100,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250211__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zLkIhPFUY9Ml" title="Warrant exercise price">1.50 per share. The Company received the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250211__20250211__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zHqEO8Tabh2h" title="Aggregate exercise price">150,000 aggregate exercise price and issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250211__20250211__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zfQFFEhrzHCh" title="Shares issued">100,000 shares of common stock to the prior holder on February 11, 2025. On February 14, 2025, the Company received a Notice of Exercise from a holder of warrants to purchase shares of common stock relating to the exercise of warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250214__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zFNnxC4rvDVg" title="Warrant purchase">80,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250214__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zwEUivRQ8WEg" title="Warrant exercise price">1.50 per share. The Company received the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250214__20250214__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zoImiblyDDEf" title="Number of shares issued value">120,000 aggregate exercise price and issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250214__20250214__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zKLwr4HuXBJj" title="Shares issued">80,000 shares of common stock to the prior holder on February 14, 2025. On June 2, 2025, the Company completed a cashless exercise of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_ecustom--StockIssuedDuringPeriodValueCashlessWarrantExercise_c20250602__20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAZht0pz0uS3" title="Cashless warrant exercise">294,643 equity-classified warrants, resulting in the issuance of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250602__20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsMe0E3IVfU7" title="Common stock issued">93,731 shares of common stock without receiving cash proceeds. The warrants carried an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250602_zQNtOWCEFp02" title="Exercise price per share">1.50 per share and were exercised in accordance with a contractual net share settlement provision. The number of shares issued was calculated using a formula set forth in the warrants that takes into account the difference between the market price and the exercise price of the warrants. Specifically, the calculation used the volume-weighted average price (VWAP) of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_c20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1mn1x6HiX4k" title="Weighted average price per share">2.20 per share on the relevant trading day, subtracted the exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250602_zTg0dkNS3OQ" title="Exercise price per share">1.50, and then multiplied the result by the number of warrants eligible for exercise, which was <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_ecustom--StockIssuedDuringPeriodValueCashlessWarrantExercise_c20250602__20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7GwXasPAyA5" title="Cashless warrant exercise">294,643. This product was then divided by the VWAP of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_c20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwPEC1j3Pq96" title="Weighted average price per share">2.20 to determine the final number of shares issued. This non-cash transaction removed <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250602_zJMd29c6hx53" title="Warrant outstanding">294,643 warrants from the Company’s outstanding instruments and added <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20250602_zAQ8QZ2fAnS8" title="Common stock shares outstanding">93,731 shares to common stock outstanding. The accounting impact was recorded within stockholders’ equity with no changes to cash or liabilities. The transaction was consistent with ASC 505-20 and reflects the Company’s approach to prudent capital management. Management continues to monitor financing arrangements to align with shareholder interests and long-term strategic growth. On June 2, 2025, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_909_ecustom--StockIssuedDuringPeriodValueCashlessWarrantExercise_c20250602__20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGbg5WbYuAu7" title="Cashless warrant exercise">224,981 shares of common stock pursuant to the cashless exercise of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_ecustom--StockIssuedDuringPeriodValueCashlessWarrantExercise_c20250602__20250602_zGVTurvASsd8" title="Cashless warrant exercise">699,143 equity-classified warrants. The warrants had an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250602_z1unEM0m36U4" title="Exercise price per share">1.50 per share and were classified as equity instruments under ASC 505-20. The warrant holder elected to exercise the warrants on a cashless basis, surrendering <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_ecustom--StockIssuedDuringPeriodValueCashlessWarrantExercise_c20250602__20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantHolderMember_zfd8iGleaJAd" title="Cashless warrant exercise">280,999 warrants in lieu of cash payment. The number of shares issued was calculated using a formula set forth in the warrants that takes into account the difference between the market price and the exercise price of the warrants. Specifically, the calculation used the volume-weighted average price (VWAP) of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_c20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG2KyHHznRk4" title="Weighted average price per share">2.20 per share on the relevant trading day, subtracted the exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250602_zody6ze6vwHk" title="Exercise price per share">1.50, and then multiplied the result by the number of warrants eligible for exercise, which was <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250602__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantHolderMember_zESO738vGqF7" title="Warrant exercise">699,143. This product was then divided by the VWAP of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_c20250602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjotcutzFgke" title="Weighted average price per share">2.20 to determine the final number of shares issued. The Company recorded: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An increase in Common Stock of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20250602__20250602__srt--RangeAxis__srt--MaximumMember_zcIPeXqK2Unl" title="APIC warrant">23; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An increase in APIC – Common Stock of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20250602__20250602_zzHkRvBGOSSe" title="APIC warrant">23.</td></tr> </table> No cash was received. The transaction was accounted for entirely within equity, and the warrants were extinguished upon exercise. On June 9, 2025, the Company received a Notice of Exercise from a holder of warrants to purchase shares of common stock relating to the exercise of warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250609_zCtfKtfujw52" title="Warrant purchase">100,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250609_zTRbZ24GgF9i" title="Warrant exercise price">1.50 per share. The Company received the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250609__20250609_zxniXbzw66Ek" title="Aggregate exercise price">150,000 aggregate exercise price and issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250609__20250609_zbxXNXnXnvv4" title="Shares issued">100,000 shares of common stock. On July 29, 2025, a holder of certain outstanding warrants of the Company, exercised warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250729_z1Ug8YH96xZ3" title="Warrant purchase">198,000 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250729_znFlG5UOOPU9" title="Warrant exercise price">1.50, for an aggregate of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250729__20250729_zqB9NETKjcN9" title="Aggregate exercise price">297,000, and was issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250729__20250729_zIuVbtqFPQ0c" title="Shares issued">198,000 net shares of common stock. On December 19, 2025, the Company completed an offering of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251219__20251219_z1Vcfv7JylRd" title="Offering of shares">1,430,502 shares of common stock at $1.295 per share and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251219_zBmnKZr240ah" title="Prefunded warrants">500,000 pre-funded warrants at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_eus-gaap--WarrantExercisePriceIncrease_c20251219__20251219_zChsuod5Cwf5" title="Warrants price">1.29499 per warrant, with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90C_eus-gaap--WarrantExercisePriceDecrease_c20251218__20251218_zUygr1jEyIM1" title="Warrants per share">0.000001, generating gross proceeds of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20251219__20251219_zKVdC1GZo2wb" title="Gross proceeds">2,499,995. Offering costs totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20251219__20251219_zyXYaYwxbeef" title="Gross proceeds from offering costs">285,000 for net funds to the Company of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_ecustom--ProceedsFromIssuanceInitialPublicOfferingNetAmount_c20251219__20251219_zSrbUkjj2XVi" title="Gross proceeds from offering costs net amount">2,224,995. On December 24, 2025, the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251224_zyHaL7l2FsL7" title="Prefunded warrants">500,000 pre-funded warrants were fully exercised for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_c20251224__20251224_zDhlKl8UT4g" title="Warrants exercise">5 net of any expenses. As part of the offering, the Company also issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251224__20251224_zU9WJ1kQwxtk" title="Issued offering">1,930,502 warrants with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251224_zgGXlULWiQS6" title="Exercise price of warrants">1.4245 that expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251224_za0JyhLPRpO4" title="Warrants expire date">December 18, 2030. In accordance with ASC 718, we have calculated the fair value to be $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20251224__20251224_zPXHuMwSJ8A2" title="Fair value of warrant">967,845 on the grant date, using the Black-Scholes Valuation Model. As of March 31, 2026 and December 31, 2025, the fair value of warrants outstanding was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20260101__20260331_z4uaps93UDr9" title="Fair value of warrant">3,579,121 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20251231_zbM6RCxSvu4d" title="Fair value of warrant">3,579,121, respectively. The warrant’s fair value was assessed on the grant date. During the three months ended March 31, 2026, there were no warrants to purchase, exercise or cancel common stock. The following table summarizes common stock warrants activity: SCHEDULE OF COMMON STOCK WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ5vwTaYusf6" style="width: 16%; text-align: right" title="Warrants Outstanding, Balance">940,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMjEXL4NP1Mc" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Balance">5.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2QhVHKNeg5" style="text-align: right" title="Warrants Granted">3,413,211</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxgVsZV1L1q2" style="text-align: right" title="Weighted Average Exercise Price Granted">1.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhhfsFEQGtq7" style="text-align: right" title="Warrants Exercised">1,425,143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8asMnOJCMV6" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.26</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsT1kkrJ1Vdi" style="text-align: right" title="Warrants Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTuush7OUqWd" style="text-align: right" title="Weighted Average Exercise Price Expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLfWuOZ77AT6" style="text-align: right" title="Warrants Cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9VWGdW6BOeb" style="text-align: right" title="Weighted Average Exercise Price Cancelled">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Outstanding, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ8zs0ab8mS2" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Balance">2,928,401</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbFhqpFgPD8a" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance">1.98</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwuRnXwxjeek" style="text-align: right" title="Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJOn52ajnvVd" style="text-align: right" title="Weighted Average Exercise Price Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDlMedf91Grc" style="text-align: right" title="Warrants Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIwF06enkMpb" style="text-align: right" title="Weighted Average Exercise Price Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXucnJTue6o" style="text-align: right" title="Warrants Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjjHLoVsbLo7" style="text-align: right" title="Weighted Average Exercise Price Expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxu1us1MMSml" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX2T7uNnnjG5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0OC5lbIKhAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Balance">2,928,401</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBAOn1AkSAFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Balance">1.98</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOXFBzP04tU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable Balance">2,928,401</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8I63YeoviJ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable price">1.98</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of March 31, 2026, warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJeK91t33pEi" title="Outstanding and vested warrants, shares">2,928,401 shares of common stock are outstanding and vested, and the vested stock warrants have a weighted average remaining life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENBUElUQUwgU1RPQ0sgLSBXQVJSQU5UUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLQGSSNZm756" title="Outstanding and vested warrants expected term">4.31 years. The aggregate initial fair value of the warrants granted in 2026 and 2025 was calculated using the Black-Scholes option pricing model based on the following assumptions: SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of common stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZhGl7BmMIRj" title="Fair Value of Common Stock on measurement date">10.90 - $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zDlUbz1EvVtd" title="Fair Value of common stock on measurement date">0.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">From <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zRoS9zVUkp8e" title="Risk-free interest rate">4.59% to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zlvexXlNUEBc" title="Risk-free interest rate">3.42</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">From <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zGmVy2c0wkqk" title="Volatility">238.00% to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zs28bUyTQw3a" title="Volatility">106.62</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDYoW6ez1tgk" title="Dividend Yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zdJGYUEbRDI2" title="Expected Term">3 - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zXXPaT9HRH43" title="Expected Term">5 years</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The trading volatility was determined by calculating the volatility of the Company’s peer group.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company does not expect to pay a dividend in the foreseeable future.</td></tr> </table>

10000000

0.0001

6000

0.0001

1100

300

300000

396000

2.61

500

500000

660000

2.59

50000

66000

2.59

250

250000

216

237600

105600

2.25

146

385000

256667

1.50

116

160600

107067

1.50

350

127602

85067

1.50

218

239800

159866

1.50

63800

42533

1.50

260

286002

190667

1.50

81402

54267

1.50

(a) reduce the conversion price set forth therein to a fixed price of $1.50 per share (subject to customary adjustments for stock splits) (compared to having a fixed conversion price of $2.25 prior to the amendment); (b) reduce the floor price set forth therein from $2.25 to $1.50 per share (subject to customary adjustments for stock splits); (c) remove the dividend rights set forth therein (except for standard participatory rights for dividends declared on the Company’s common stock)

350

385000

256667

1.50

100

100000

100

110000

73333

1.50

300

330000

220000

1.50

100

110000

73333

1.50

500

550000

366667

1.50

35200

23467

1.50

6250000

0.0001

980000

2272109

1979109

20000000

980000

20.00

19600000

400000

(i) with $200,000 payable on or before June 30, 2024, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024.

27000

147451

200000000

0.0001

16967421

15888795

400000

1100000

0.74

296000

On January 12, 2026, we entered into another service agreement with Greentree. The Company and Greentree were previously party to a service agreement which expired pursuant to its terms on September 30, 2025. The Company agreed to issue Greentree 40,000 shares of the Company’s restricted common stock upon the parties’ entry into the agreement (fully-earned upon issuance), and to pay Greentree $40,000 in cash, payable as follows: (a) $20,000 on or before January 15, 2026; and (b) $20,000 on or before March 31, 2026, which is still due and outstanding as of the date of this report.

40000

0.785

31400

75000

0.537

40275

313625

0.384

120463

250000

0.404

101000

83333

50000

33333

16.50

P5Y

10000

16.50

P5Y

83333

4.80

P5Y

18889

14444

13333

5.55

P3Y

2000000

P10Y

2.30

500000

0.45

50000

16.50

83333

4.80

2000000

2.30

37978

1090114

50979

The following table summarizes common stock option activity: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20250101__20251231_zAMfinXaFIS3" style="width: 16%; text-align: right" title="Options, Exercisable Beginning Balance">156,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20250101__20251231_zpszhe2slvgg" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">9.34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zw7ci0MbRtQb" style="text-align: right" title="Options, Granted">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231_zv1ZRPIgCqj7" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20251231_zJDmGoiVtbW2" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231_z5XHy5iQm2t3" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Expired / Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250101__20251231_zaDrkTBp1onk" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231_zHk5WgKikMtk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20260101__20260331_z4LdQIRs4fLf" style="text-align: right" title="Options, Exercisable Beginning Balance">2,156,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20260101__20260331_zmDNGMybRSIc" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331_zQb5fUa8oILg" style="text-align: right" title="Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331_z0T6eogPMdy5" style="text-align: right" title="Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260331_z789bRkAHvAh" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331_zfb8SU7k0kTb" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired / Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260331_z4LTbnhZfA07" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331_zwR6caSr5TDb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331_z4JLFkxtdDKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding Ending Balance">2,156,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331_zQTxc7Ti9ET9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331_zAFZg9G5kzla" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable Ending Balance">1,156,110</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331_zmMDD6FDtSAd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.65</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

156666

9.34

2000000

0.45

2156666

0.56

2156666

0.56

1156110

0.65

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zZnNQYNcfkh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The weighted average exercise prices, remaining lives for options granted, and exercisable as of March 31, 2026 were as follows: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options Exercise Price Per Share</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Life (Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zKsAdY4nFych" style="width: 13%; text-align: right" title="Weighted Average Outstanding">16.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeG8OHMLJbZ1" style="width: 13%; text-align: right" title="Outstanding Options">10,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zyox2IiV3MV9" title="Options Term">.47</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXyJYDOt3sob" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price">16.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zQEMGzZ9i6N8" style="width: 13%; text-align: right" title="Exercisable Options">9,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zb4MG9zgftzd" style="width: 13%; text-align: right" title="Weighted Average Exercise Price, Exercisable">16.50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zA98vy3q5Hqd" style="text-align: right" title="Weighted Average Outstanding">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zYAlpAiMdTb3" style="text-align: right" title="Outstanding Options">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ztslH4BDIA0c" title="Options Term">.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSIkU7KQhMt7" style="text-align: right" title="Weighted Average Exercisable Price">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSfWASOPNDV9" style="text-align: right" title="Exercisable Options">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKBKYLG41h6j" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zvdWRJv5iFs8" style="text-align: right" title="Outstanding Options, Exercise Price Per Share">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zR9l7xwzBk77" style="text-align: right" title="Outstanding Options, shares">83,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zLuaKl8UIy6" title="Outstanding Options, Life (Years)">.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zaxwhxKiELE4" style="text-align: right" title="Exercisable Options, Weighted Average Exercise Price">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z78oJmz1VSm5" style="text-align: right" title="Exercisable Options, Shares">83,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zslqRaztKpPe" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z1K36JtjEPqh" style="text-align: right" title="Outstanding Options, Exercise Price Per Share">5.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zw3hWioQ2WA7" style="text-align: right" title="Outstanding Options, shares">13,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zeuYaQqEFpKi" title="Outstanding Options, Life (Years)">.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zSCjTgvY3827" style="text-align: right" title="Exercisable Options, Weighted Average Exercise Price">5.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zW7F3sRDkwH5" style="text-align: right" title="Exercisable Options, Shares">13,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zFWxncDlHRVj" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">5.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zRD38nlxX406" style="text-align: right" title="Outstanding Options, Exercise Price Per Share">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zqJW8Qs3iIR2" style="text-align: right" title="Outstanding Options, shares">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYnHGtFdHFMl" title="Outstanding Options, Life (Years)">9.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2y6H8XvJ8Q3" style="text-align: right" title="Exercisable Options, Weighted Average Exercise Price">0.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zQ84sw5ooCKg" style="text-align: right" title="Exercisable Options, Shares">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2zrK5iMfnJc" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.45</td><td style="text-align: left"> </td></tr> </table>

16.50

10000

P0Y5M19D

16.50

9444

16.50

0.45

50000

P0Y1M2D

0.45

50000

0.45

83333

P0Y2M4D

0.45

83333

0.45

5.55

13333

P0Y1M2D

5.55

13333

5.55

0.45

2000000

P9Y5M12D

0.45

1000000

0.45

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z866qrlMK8A6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of common stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__srt--RangeAxis__srt--MaximumMember_z45bchdLAcy9" title="Fair value of common stock on measurement date">30.47 – <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__srt--RangeAxis__srt--MinimumMember_zJx7ODxMFAma" title="Fair value of common stock on measurement date">0.37</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zSo4bjAtHsY2" title="Risk free interest rate">4.13% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zW8B6zDHSnje" title="Risk free interest rate">4.10</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zZID7z0gSKo" title="Volatility">145.38% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zyTXhgFoZ4E9" title="Volatility">125.78</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zzRn7qjgnyic" title="Expected Term">5.75 - <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zFKhX3NqMZP4" title="Expected Term">3.0</td><td style="text-align: left"> </td></tr> </table>

30.47

0.37

0.0413

0.0410

1.4538

1.2578

P5Y9M

P3Y

2000000

1.00

15.00

2000000

65033

5833

75.00

P5Y

31995

18667

5.70

P5Y

78174

2800

5.63

12086

220000

3.90

681352

66667

7.50

260750

33333

15.00

122341

6250

13000

4.35

56160

20000

68170

528000

2.62

1193887

300

300000

396000

2.61

500

500000

660000

2.59

50000

66000

2.59

2226602

140000

1.50

210000

140000

100000

1.50

150000

100000

80000

1.50

120000

80000

294643

93731

1.50

2.20

1.50

294643

2.20

294643

93731

224981 699143

1.50

280999

2.20

1.50

699143

2.20

100000

1.50

150000

100000

198000

1.50

297000

198000

1430502

1.295

500000

1.29499

0.000001

2499995

285000

2224995

500000

1930502

1.4245

2030-12-18

967845

3579121

The following table summarizes common stock warrants activity: SCHEDULE OF COMMON STOCK WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ5vwTaYusf6" style="width: 16%; text-align: right" title="Warrants Outstanding, Balance">940,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMjEXL4NP1Mc" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Balance">5.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2QhVHKNeg5" style="text-align: right" title="Warrants Granted">3,413,211</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxgVsZV1L1q2" style="text-align: right" title="Weighted Average Exercise Price Granted">1.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhhfsFEQGtq7" style="text-align: right" title="Warrants Exercised">1,425,143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8asMnOJCMV6" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.26</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsT1kkrJ1Vdi" style="text-align: right" title="Warrants Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTuush7OUqWd" style="text-align: right" title="Weighted Average Exercise Price Expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLfWuOZ77AT6" style="text-align: right" title="Warrants Cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9VWGdW6BOeb" style="text-align: right" title="Weighted Average Exercise Price Cancelled">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Outstanding, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ8zs0ab8mS2" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Balance">2,928,401</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbFhqpFgPD8a" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance">1.98</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwuRnXwxjeek" style="text-align: right" title="Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJOn52ajnvVd" style="text-align: right" title="Weighted Average Exercise Price Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDlMedf91Grc" style="text-align: right" title="Warrants Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIwF06enkMpb" style="text-align: right" title="Weighted Average Exercise Price Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXucnJTue6o" style="text-align: right" title="Warrants Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjjHLoVsbLo7" style="text-align: right" title="Weighted Average Exercise Price Expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxu1us1MMSml" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX2T7uNnnjG5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0OC5lbIKhAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Balance">2,928,401</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBAOn1AkSAFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Balance">1.98</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOXFBzP04tU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable Balance">2,928,401</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8I63YeoviJ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable price">1.98</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

940333

5.08

3413211

1.47

1425143

1.26

2928401

1.98

2928401

1.98 2928401 1.98

2928401

P4Y3M21D

SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of common stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZhGl7BmMIRj" title="Fair Value of Common Stock on measurement date">10.90 - $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zDlUbz1EvVtd" title="Fair Value of common stock on measurement date">0.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">From <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zRoS9zVUkp8e" title="Risk-free interest rate">4.59% to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zlvexXlNUEBc" title="Risk-free interest rate">3.42</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">From <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zGmVy2c0wkqk" title="Volatility">238.00% to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zs28bUyTQw3a" title="Volatility">106.62</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDYoW6ez1tgk" title="Dividend Yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zdJGYUEbRDI2" title="Expected Term">3 - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zXXPaT9HRH43" title="Expected Term">5 years</td><td style="text-align: left"> </td></tr> </table>

10.90

0.50

0.0459

0.0342

2.3800

1.0662

P3Y

P5Y

NOTE 7 – GOING CONCERN These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the next twelve months. As reflected in the accompanying consolidated financials, the Company had a net loss of $3,403,141 for the three months ended March 31, 2026 and an accumulated deficit of $44,050,630 as of March 31, 2026. The Company will need to raise additional capital to successfully execute its business plan of which there can be no assurance. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing shareholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity, or force us to abandon our business plan. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the 12 months from date of issuance of this filing. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

-3403141

-44050630

NOTE 8 – COMMITMENTS AND CONTINGENCIES In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business. On October 31, 2024, Eli Lilly and Company (“Eli Lilly”) filed a complaint against us in the Northern District of Texas Dallas Division. The complaint alleges causes of action against us for false and misleading advertising and promotion in violation of Section 43(a)(1)(B) of the Lanham Act; and false advertising, in connection with the Company’s TRIM product, and seeks (a) a declaratory judgment, an injunction from falsely stating or suggesting that our oral dissolvable tirzepatide tablets are approved by the FDA, have been the subject of clinical studies, or achieve certain therapeutic outcomes; engaging in any unfair competition with Eli Lilly; and engaging in any deceptive or unfair acts; (b) an order requiring the Company and its officers, agents, servants, employees, and attorneys and all persons acting in concert or participation with any of them, to engage in corrective advertising by informing consumers that: a. our oral dissolvable tirzepatide tablets do not contain the same formulation as MOUNJARO® or ZEPBOUND®; b. our oral dissolvable tirzepatide tablets do not contain the same dosage as MOUNJARO® or ZEPBOUND®; c. our oral dissolvable tirzepatide tablets are not and have never been approved by the FDA; d. our oral dissolvable tirzepatide tablets have never been studied in clinical trials; and d. our oral dissolvable tirzepatide tablets have never been demonstrated to be safe or effective; (c) an order directing the Company to file with the court and serve on Eli Lilly’s attorneys, thirty (30) days after the date of entry of any injunction, a report in writing and under oath setting forth in detail the manner and form in which it has complied with the court’s injunction; (d) an order requiring the Company to account for and pay to Eli Lilly any and all profits arising from the foregoing acts of alleged false advertising; (e) an order requiring the Company to pay Eli Lilly compensatory damages in an amount as of yet undetermined caused by the false advertising and trebling such compensatory damages for payment to Lilly in accordance with 15 U.S.C. § 1117 and other applicable laws; (f) an order requiring the Company to pay Eli Lilly all types of monetary remedies available under Texas state law in amounts as of yet undetermined caused by the foregoing acts of unfair competition; (g) pre-judgment and post-judgment interest on all damages; and (h) attorney’s fees. As discussed above, the initial Complaint asserted two claims: (i) false advertising under the federal Lanham Act; and (ii) common law deceptive advertising. The Company moved to dismiss the second claim, arguing that Texas does not recognize such a claim. Thereafter, on January 30, 2025, Eli Lilly responded by filing an amended complaint wherein it removed the 2nd cause of action. On February 24, 2025, the Company filed its response along with its affirmative defenses and concluding with a motion to dismiss. On June 23, 2025, the Company and Eli Lilly entered into a Confidential Settlement and Mutual Release Agreement whereby both parties agreed to settle and resolve the complaint upon the Company agreeing pay Eli Lilly a total of $20,000 in cash (the “Settlement Amount”) and the Company agreeing to refrain from marketing and selling its Tirzepatide based ‘TRIM’ products on its MangoRx.com website in the future. The Company paid the Settlement Amount on June 27, 2025 and the dispute has been settled in full. On February 18, 2025, Boustead brought an arbitration action against the Company with the Financial Industry Regulatory Authority (“FINRA”) claiming fees for services owed to Boustead pursuant to its original Engagement Agreement and Advisory Services Agreement entered into with Boustead on June 21, 2022 (the “Boustead Agreement”). Specifically, Boustead is claiming the Company owes Boustead in excess of $1,000,000 in cash and warrants for various financial advisory related services for transactions in which the Company did not engage or retain any financial advisor and in which the Company entered into on its own accord. Furthermore, all transactions in which they are claiming fees transpired after the Right of First Refusal provision of the Boustead Agreement terminated on or around March 20, 2024. The Company believes this is an ill-willed attempt for Boustead to receive fees in which they are not entitled and that this claim has no basis or merit. The Company intends to vigorously defend itself against this claim with FINRA through arbitration. On May 5, 2025, the Company entered into a Compromise Settlement Agreement and Mutual Release (the “Settlement”) between the Company, Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman and 1800 Diagonal Lending, LLC (“1800 Diagonal”). Pursuant to the Settlement and in consideration for general releases of all parties, and the dismissal of a lawsuit with prejudice, pursuant to which 1800 Diagonal has made claims against the Company and Mr. Cohen, the Company agreed to issue 1800 Diagonal <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250505__20250505__us-gaap--TypeOfArrangementAxis__custom--CompromiseSettlementAgreementAndMutualReleaseMember_zb1aVfWlQ4of" title="Restricted common stock">62,500 shares of restricted common stock of the Company (the “Settlement Shares”). The Settlement Agreement was entered into following a mediation between the parties. The shares were issued on May 5, 2025 with a fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250505__20250505__us-gaap--TypeOfArrangementAxis__custom--CompromiseSettlementAgreementAndMutualReleaseMember_zsOP7Poxv6ii" title="Fair value of shares issued">105,625. In connection with the appointment of Mr. Antonios Isaac as a member of the Board of Directors of the Company and as President of the Company, the Company entered into a Consulting Agreement with Mr. Isaac on January 15, 2025 (the “Isaac Consulting Agreement”). Pursuant to the Isaac Consulting Agreement, Mr. Isaac agreed to serve as the President of the Company and to provide services to the Company as reasonably requested during the term of the Isaac Consulting Agreement, which is 12 months. As consideration for the services to be provided by Mr. Isaac under the Isaac Consulting Agreement, the Company agreed to pay him $10,000 per month. Pursuant to the Isaac Consulting Agreement, we agreed to reimburse Mr. Isaac’s expenses, subject to pre-approval for any expense greater than $500. On July 1, 2025, Mr. Antonios Isaac, the Company’s President and member of the Board of Directors, provided notice to the Company of his resignation as both a member of the Board of Directors and President, which terminated the Isaac Consulting Agreement. On January 27, 2025, the Company entered into a First Amendment to Payment Plan Letter Agreement (the “1st Amendment”) with MAAB Global Ltd. (“MAAB”). MAAB had previously purchased rights to $500,000 owed by the Company to Barstool Sports, Inc. (“Barstool” and the “Debt”) on January 10, 2025, which amount was non-interest bearing, and due pursuant to the terms of a Payment Plan Letter Agreement entered into between Barstool and the Company on August 27, 2024. Pursuant to the 1st Amendment, the Company and MAAB agreed to amend the terms of the Debt to allow MAAB the right, exercisable at any time, to convert the $500,000 of Debt into shares of the Company’s common stock at a conversion price of $1.50 per share. See Note 7 for further details regarding the request to convert the Note to shares of common stock. On August 6, 2025, the Company filed a lawsuit in the 191st Judicial District Court of Dallas, County in Dallas, Texas against its former technology consulting and software development firm, Clarity Ventures, Inc. (“Clarity”). The Company alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource planning (“ERP”) and eCommerce platform that Clarity had been engaged to design and implement in support of the Company’s operations. The lawsuit seeks damages exceeding $73 million, exclusive of interest, costs, and attorneys’ fees. Clarity has denied the Company’s allegations and has asserted counterclaims related to alleged unpaid invoices. The Company believes these counterclaims are unwarranted, as all binding and required payments under the applicable agreements were made in full prior to disengaging from Clarity’s services. The Company intends to vigorously pursue its claims and defend against the counterclaims through the litigation process. As of the date of this report, the Company has filed with the courts its first set of interrogatories, requests for production, and requests for admissions. On January 12, 2026, we entered into another service agreement with Greentree. The Company and Greentree were previously party to a service agreement which expired pursuant to its terms on December 31, 2025. Since February 2015, Mr. Eugene M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022), has served as Audit Manager for Greentree. Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) assistance to the Company with compliance filings for the quarters ended March 31, 2026, June 30, 2026, September 30, 2026, and the year ended December 31, 2025, including the consolidation structure and entries as well as assistance with United States Generally Accepted Accounting Principles (“US GAAP”) footnotes; (b) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the Securities and Exchange Commission (the “SEC”); (c) providing necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys, certified public accountants and transfer agent; and (d) preparing and filing the Company’s tax returns with the Internal Revenue Service for the 2025 tax year. <span id="xdx_90B_eus-gaap--RestrictedCashAndCashEquivalentItemDescription_c20260112__20260112__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementLSTMMember_zI6SaLrkmCuj" title="Restricted cash and cash equivalent, nature of restriction, description">The Company agreed to issue Greentree <span id="xdx_907_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20260112__20260112__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementLSTMMember_zXdB0FFPo62" title="Restricted stock, shares issued net of shares for tax withholdings">40,000 shares of the Company’s restricted common stock upon the parties’ entry into the agreement (fully-earned upon issuance), and to pay Greentree $40,000 in cash, payable as follows: (a) $20,000 on or before January 15, 2026; and (b) $20,000 on or before March 31, 2026. We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree’s activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The 40,000 shares were issued to Greentree at a price of $0.785 per share for a total of $31,400. The Service Agreement continued in effect through November 14, 2026, but may be terminated earlier with 45 days’ notice from the Company to Greentree, provided that in the event the Company terminates the agreement prior to the end of the Term, the entire cash fee due during the term of the Service Agreement is immediately due and payable. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. Concurrent with the Greentree service agreements described above, Mr. Johnston also maintains a separate personal consulting agreement with the Company pursuant to which he serves as the Company’s Chief Financial Officer. Under his personal consulting agreement. Mr. Johnston does not receive any compensatory benefit from the agreement with Greentree. Mr. Johnston’s personal compensation is separately disclosed in Item 11 — Executive Compensation. The Company’s Audit Committee has reviewed and approved both the Greentree service agreements and Mr. Johnston’s personal consulting arrangement on arms-length terms. RELATED PARTIES On April 24, 2025, we entered into a First Amendment to Amended and Restated Executive Employment Agreement with Jacob D. Cohen, our Chief Executive Officer (the “Amendment”). The Amendment, which has an effective date of April 1, 2025, amended that prior Amended and Restated Executive Employment Agreement dated December 13, 2024, by and between the Company and Mr. Cohen, as amended to date (the “A&R Agreement”) to: (a) provide for Mr. Cohen to be paid a bonus of an additional <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250424__20250424__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__dei--LegalEntityAxis__custom--MangoAndPeachesMember_zyJzfPyuesci" title="Number of shares issued">4,892,906 shares of Mango & Peaches, a subsidiary of the Company, common stock (the “M&P Stock”); (b) increase Mr. Cohen’s base yearly compensation to $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250424__20250424__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrCohenMember__srt--RangeAxis__srt--MaximumMember_zOCRX3jyqtr4" title="Stock based compensation">420,000 per year (from $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20250424__20250424__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__dei--LegalEntityAxis__custom--MangoAndPeachesMember__srt--RangeAxis__srt--MinimumMember_zbwI0nPOizJb" title="Stock based compensation">360,000 per year); (c) increase the monthly office allowance payable to Mr. Cohen to $<span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250424__20250424__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrCohenMember__srt--RangeAxis__srt--MaximumMember_z5gLYI3q20Tj" title="Allowance payable">10,000 (from $<span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250424__20250424__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrCohenMember__srt--RangeAxis__srt--MinimumMember_zUheMybcS5Eg" title="Allowance payable">7,500); and (d) increase the monthly car allowance payable to Mr. Cohen to $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20250424__20250424__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrCohenMember__srt--RangeAxis__srt--MaximumMember_zs33oI0nm1yb" title="Car allowance payable">5,000 per month (from $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250424__20250424__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrCohenMember__srt--RangeAxis__srt--MinimumMember_zHWH7IlLoW6k" title="Car allowance payable">2,500). As of March 31, 2026, the Company had overpaid the car allowance by $<span id="xdx_90D_eus-gaap--OtherLiabilitiesCurrent_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedExecutiveEmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--MrCohenMember_zJCXajIa9bs2" title="Due from related party">20,056, reflected as due from related party on the financial statements. On March 20, 2026 and effective on October 1, 2025, the Company entered into a Consulting agreement with Mr. Johnston, the Company’s Chief Financial Officer, pursuant to which Mr. Johnston agreed to serve as the Chief Financial Officer of the Company and to provide services to the Company as reasonably requested during the term of the Consulting Agreement, which is 12 months. As consideration for the services to be provided by Mr. Johnston under the Consulting Agreement, the Company agreed to pay him (a) $4,000 per month and increasing to $<span id="xdx_904_eus-gaap--ProfessionalFees_c20260320__20260320__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zaStUTZqqzd5" title="Consideration for services, increased">6,000 per month effective March 1, 2026; Pursuant to the Consulting Agreement, we agreed to reimburse Mr. Johnston’s expenses, subject to pre-approval for any expense greater than $500. The Consulting Agreement may be terminated prior to the end of the term (i) with the mutual approval of the parties; (ii) with written notice by the non-breaching party, upon the breach of the agreement by the other party, and the failure to cure such breach within 30 days; or (iii) by Mr. Johnston, at any time, for any reason. The Consulting Agreement also contains standard assignment of inventions, indemnification and confidentiality provisions, subject to customary exceptions. Further, Mr. Johnston is subject to certain non-solicitation covenants during the term of the agreement and for 12 months thereafter. Mr. Johnston is also eligible for discretionary equity bonuses and/or cash awards, from time to time in the discretion of the Compensation Committee and/or Board of Directors. Mr. Johnston’s compensation under the Consulting Agreement may be increased from time to time, by the Compensation Committee, or the Board of Directors (with the recommendation of the Compensation Committee), which increases do not require the entry into an amended Consulting Agreement. License Agreement and Master Distribution Agreement On May 14, 2025, MangoRx IP, the Company’s wholly-owned subsidiary, entered into a Master Distribution Agreement with PrevenTech Solutions, LLC (“PrevenTech” and the “PrevenTech MDA”). Pursuant to the PrevenTech MDA, the Company granted PrevenTech the exclusive, worldwide, licensing and distribution rights, to certain intellectual property and patent rights held by the Company relating to respiratory illness prevention technology, including the right to sell antiviral products, including but not limited to toothpaste, lozenges, mouthwash, oral sprays, and animal feed or water additives for poultry and livestock, which may be manufactured and/or designed in a various formats, using the patents. In consideration for the rights under the PrevenTech MDA, PrevenTech agreed to pay us 10% of the net sales revenue (as described in greater detail in the PrevenTech MDA) generated during the term of the PrevenTech MDA through the sale of products associated with our patents. The term of the PrevenTech MDA is perpetual, subject to certain termination rights that either party can exercise upon a breach of the agreement by the other party, subject to certain cure rights. Additionally, if PrevenTech does not generate at least $5 million of gross sales from the sale of products within eighteen months from June 1, 2025, subject to a sixty-day cure period, PrevenTech’s rights under the PrevenTech MDA become non-exclusive. The PrevenTech MDA contains customary confidentiality provisions, representations and warranties of the parties, indemnification obligations, disclaimers and covenants, for an agreement of type and size of the PrevenTech MDA. as of March 31, 2026, there have been no reported sales in conjunction with the license agreement.

20000

1000000

62500

105625

10000

500

500000

1.50

73000000

The Company agreed to issue Greentree 40,000 shares of the Company’s restricted common stock upon the parties’ entry into the agreement (fully-earned upon issuance), and to pay Greentree $40,000 in cash, payable as follows: (a) $20,000 on or before January 15, 2026; and (b) $20,000 on or before March 31, 2026.

40000

0.785

31400

4892906

420000

360000

10000

7500

5000

2500

20056

4000

6000

500

0.10 5000000

NOTE 9 – OPERATING LEASES The Company has a lease for an office in Dallas, Texas classified as operating leases under ASC 842. Effective November 1, 2025, the Company entered into a Lease Agreement (the “Lease”) with SVHQ, LLC (the “Landlord”) to lease and occupy approximately <span id="xdx_90E_eus-gaap--AreaOfLand_iI_pid_usqft_c20251101__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PremisesMember__dei--LegalEntityAxis__custom--SVHQLLCMember_zkaN47MYdcRg" title="Lease area">2,467 square feet of office space located at 17130 Dallas Parkway, Dallas, Texas 75248, Suite 245 (the “Premises”). The Lease also includes the non-exclusive right, in common with Landlord, to use and occupy an adjacent shared space consisting of approximately <span id="xdx_909_eus-gaap--AreaOfLand_iI_pid_usqft_c20251101__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SharedSpaceMember__dei--LegalEntityAxis__custom--SVHQLLCMember_zyVNuifiuPA8" title="Lease area">1,253 square feet (the “Shared Space”). The Lease has a term of sixty (60) months, commencing on November 1, 2025 and expiring on October 31, 2030, and has a monthly base rent of $4,852, including $<span id="xdx_904_eus-gaap--PaymentsForRent_c20251101__20251101__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PremisesMember__dei--LegalEntityAxis__custom--SVHQLLCMember_zThsMjogttCj" title="Rent premises">3,803 for the Premises and $<span id="xdx_90F_eus-gaap--PaymentsForRent_c20251101__20251101__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SharedSpaceMember__dei--LegalEntityAxis__custom--SVHQLLCMember_zFiZ9wGMyQi4" title="Base rent">966 for the Shared Space (the “Base Rent”). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real estate taxes and assessments, insurance, and common area maintenance costs for the building at the rate of 14.81%, consisting of 11.81% for the Premises and 3.00% for the Shared Space (the “Additional Rent”). Upon the execution of the Lease, the Company has agreed to prepay the first full month’s Base Rent and Additional Rent, consisting of $6,141, along with a security deposit equal to $14,557. The Lease includes a right of first refusal to purchase the Premises, but not the Shared Space, on the same terms and conditions as those offered by Landlord to any bona fide third-party purchaser during the term. The Lease includes customary representations of the Company and the Landlord. The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 8% to estimate the present value of the right-of-use liability. The Company has right-of-use assets of $294,061 and operating lease liabilities of $294,023 as of March 31, 2026. Operating lease expense for the three months ended March 31, 2026 was $6,141. The Company has recorded $0 in impairment charges related to right-of-use assets during the three months ended March 31, 2026. SCHEDULE OF MATURITY OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities at March 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930_z8zyV6KQjRf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzowI_zrE3uY424yx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzowI_zFhDFO1LSXT4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,697</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzowI_z7cWPLPG8Bml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,697</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzowI_z8FADXg6aaGb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Later years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,253</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zr5TLmGGKod1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">343,920</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNfDavTvzWl3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(49,898</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zFkYQzGU76M7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">294,023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2467

1253

The Lease has a term of sixty (60) months, commencing on November 1, 2025 and expiring on October 31, 2030, and has a monthly base rent of $4,852, including $3,803 for the Premises and $966 for the Shared Space (the “Base Rent”). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real estate taxes and assessments, insurance, and common area maintenance costs for the building at the rate of 14.81%, consisting of 11.81% for the Premises and 3.00% for the Shared Space (the “Additional Rent”). Upon the execution of the Lease, the Company has agreed to prepay the first full month’s Base Rent and Additional Rent, consisting of $6,141, along with a security deposit equal to $14,557

P60M

2030-10-31

4852

3803

966

6141

14557

0.08

294061

294023

6141

SCHEDULE OF MATURITY OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities at March 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930_z8zyV6KQjRf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzowI_zrE3uY424yx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzowI_zFhDFO1LSXT4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,697</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzowI_z7cWPLPG8Bml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,697</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzowI_z8FADXg6aaGb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Later years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,253</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zr5TLmGGKod1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">343,920</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNfDavTvzWl3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(49,898</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zFkYQzGU76M7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">294,023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

55273

73697

141253

343920

49898

294023

NOTE 10 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the consolidated balance sheet date but before the condensed consolidated financial statements are issued. Based on the evaluation, the Company identified the following subsequent events: On April 27, 2026, we entered into an Extension Agreement related to the Consulting Agreement with LSTM whereby the Company agreed to extend the term of the agreement by an additional six (6) months until November 2, 2026. In consideration for agreeing to the extension, the Company issued LSTM <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_pid_c20260427__20260427__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKuKCFeVz0C6" title="Number of shares issued to LSTM">200,000 shares of common stock, which were issued under the Company’s 2022 Plan. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20260427__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZztu97yVHi3" title="Share price per share">0.40 per share for a total of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20260427__20260427__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zC9diiSuZmZ6" title="Value of shares issued to LSTM">80,000. On May 18, 2026, M&P and Jacob Cohen, the Company’s Chief Executive Officer and Chairman, entered into a Clarification Agreement (the “Clarification Agreement”), effective as of May 13, 2025, the date on which the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260518__20260518__us-gaap--TypeOfArrangementAxis__custom--ClarificationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSqvLZm2aDhd" title="Number of shares issued">4,892,906 shares of M&P common stock (the “Shares”) were originally issued to Mr. Cohen. The Clarification Agreement confirms that it was never the intent of the parties that Mr. Cohen would participate in, bear responsibility for, or be allocated any losses, liabilities, deficits, or other negative economic attributes of M&P by virtue of his ownership of the Shares. The Clarification Agreement further confirms that Mr. Cohen retains the right to participate in positive economic value associated with the Shares, including any appreciation in value, dividends, distributions, or proceeds upon a sale, merger, or liquidation, subject to M&P’s organizational documents and applicable law. As of March 31, 2026, M&P has an accumulated deficit and no current positive equity value. Accordingly, no noncontrolling interest has been recognized in the condensed consolidated financial statements of the Company with respect to Mr. Cohen’s interest in M&P, as any such balance is de minimis and immaterial. This conclusion will be reassessed in future periods.

200000

0.40

80000

4892906

false false false false